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ABSTRACT
The polypeptide composition of purified radioactively labeled 
equine infectious anemia virus (EIAV) was investigated using 
high-resolution sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and guanidine hydrochloride gel filtration 
(GHC1-GF) to catalog key biochemical properties including molecular 
weights, stoichiometry, isoelectric points and modifications 
(glycosylation or phosphorylation). The results of these studies 
indicate that EIAV contains four major nonglycosylated proteins (p26, 
ppl5, pll, and p9) and two glycoproteins (gp90 and gp45), which 
together account for greater than 95% of the total virion protein.
Four minor polypeptides (p70, p61, p30, and p23) of unknown 
significance were also detected reproducibly. Comparisons of the 
major purified proteins by peptide mapping procedures demonstrated the 
unrelatedness of the proteins, including two glycoproteins, gp90 and 
gp45.
Localization experiments indicated that gp90 and gp45 constitute 
the envelope glycoproteins while nonglycosylated polypeptides (p26, 
ppl5, pll and p9) constitute the internal components of the virus.
EIAV pll is closely associated with the viral genome in a 
ribonucleoprotein complex and ppl5 seems to be a component of inner 
coat while p26 and p9 appear to comprise the icosahedral core shell. 
Thus, our results demonstrated that EIAV, a putative lentivirus, 
contains polypeptides analogous to the structural polypeptides of 
prototype-C oncornaviruses (Montelaro and Bolognesi, 1980).
vii
The recurrent nature of equine infectious anemia (EIA) has been 
attributed to relatively rapid antigenic variations in EIAV during 
persistent infection under selective immune pressures. This model was 
tested by biochemical analyses of five serologically distinct EIAV 
isolates, recovered from experimentally inoculated ponies (Orrego, 
1983). Comparative SDS-PAGE analysis of proteins and two-dimensional 
peptide mapping of their tryptic digests revealed that gp90 and gp45 
undergo structural alterations during virus replication. No 
differences were found in the internal antigens after virus replicated 
in a single animal; however, EIAV p26 did indicate a few structural 
variations when the virus was passaged into another animal.
Thus, serological differences among EIAV isolates are correlated 
to the structural variations in the polypeptides of EIAV. The 
capacity to alter antigenic structure, especially envelope 
glycoproteins, may represent an important mechanism for retroviral 




EQUINE INFECTIOUS ANEMIA, THE DISEASE
Equine infectious anemia (EIA) is an acute hemolytic disease of 
horses, caused by a nononcogenic retrovirus (Archer et al., 1977; 
Charman et al., 1976; Cheevers et al., 1977; Nakajima et al., 1969, 
1970; Tajima et al., 1969). Historically one of the first diseases 
shown to be caused by a virus (Vallee and Carre, 1904), it has been 
known for about 80 years. Progress has been made only within the last 
several years toward understanding the disease at the cellular and 
molecular level. Colloquially called swamp fever, it occurs in the 
members of the family equidae (Issel and Coggins, 1979). In the 
United States, Louisiana has the highest reported incidence of the 
disease. From 1976 to 1981, about 5% of the horses sampled in this 
state tested positive for EIA, but in some areas of Louisiana the 
infection rate may be as high as 30 to 40% (Foil and Issel, 1982).
Clinical Symptoms
EIA is unique among retrovirus infections because of its episodic 
character (Crawford et al., 1978; Issel and Coggins, 1979; Orrego et 
al., 1982). Following infection, the disease is not progressive, but 
occurs during unpredictable "cycles", between which the horse may be 
clinically normal. Clinical symptoms and associated bursts of viremia 
occur in sequential episodes, separated by several weeks or months.
The clinical response of horses following artificial inoculation or 
natural exposure to equine infectious anemia virus (EIAV) is variable
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and depends, in part, on host resistance factors, viral virulance and 
environmental factors. Horses developing the clinical disease EIA 
have been described as acute, subacute or chronic cases.
Acute Cases - Acute EIA is most often associated with the first 
exposure to the virus and results from massive virus replication in 
infected macrophages and their eventual destruction. Clinical signs 
include fever and hemorrhages. Neither anemia nor edema are seen at 
this stage.
Subacute and Chronic Cases - Horses with the chronic form of EIA 
have unpredictable periodic episodes of illness during which more 
classical clinical signs of EIA, such as loss of weight, anemia, 
subcutaneous edema, lethargy, leukopenia and depression of central 
nervous system are observed (Orrego et al., 1982).
Many of the clinical signs in horses with chronic EIA may be due 
to changes induced by immune reactions to viral products (Henson and 
McGuire, 1971). The anemia observed during disease may be explained 
on this basis, although pathogenesis of the anemia has not been 
elucidated. Since EIAV possesses a hemagglutinin (Sentsui and Kono, 
1976; Sentsui and Kono, 1981), virus particles may attach to 
erythrocytes, and specific immunoglobulins then attach to viral 
proteins. The immune complexes on the cell surface would then attract 
the complement. The complement coated erythrocytes are found in 
anemic EIAV-infected horses (Perryman et al., 1971), and the affected 
erythrocytes have a short life span and are phagocytized by leukocytes 
(McGuire et al., 1969).
Occasionally, affected horses undergo the initial febrile attack 
and remain asymptomatic for the remainder of their lives.
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Nevertheless, they harbor the virus for life. A high percentage of 
infected horses exhibit no clinical symptoms associated with 
infection, although the virus or the viral products could be detected 
by agar gel immunodiffusion (AGID) test (see below) in blood of such 
animals (Kemen and Coggins, 1972; Issel et al., 1982). Such 
apparently healthy but infected animals seem to play an important role 
in the spread of this virus by interrupting blood feeding insect 
vectors (Foil and Issel, 1982).
Transmission
Transmission of EIA is mainly horizontal and rarely vertical. 
Horizontal transmission may result from hematophagous arthropod 
insects, feeding on horse blood (Foil et al., 1982; Issel and Coggins, 
1979; Williams et al., 1981), or from use of contaminated instruments 
or syringes while transferring infective blood or blood products 
(Issel and Coggins, 1979). The potential for transmission from an 
infected donor appears to be higher in the presence of clinical signs 
than in absence. This seems to be directly correlated with the level 
of free virus in the donor's blood and tissues. The virus can be 
demonstrated in the secretions and excretions of horses with acute 
EIA. The virus apparently can cross the placental barrier and cause 
fetal infection. However, more than 75 percent of the foals from 
infected mares can be raised free of EIA (Foil and Issel, 1982; Kemen 
and Coggins, 1972).
Diagnosis
EIA can be diagnosed on the basis of its typical clinical signs, 
hematology, pathology or by specific laboratory tests. Clinical signs
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are not always specific, hence more specific laboratory tests are 
important and useful in the diagnosis of this disease. Laboratory 
tests involve the detection of virus or EIA specific antibody in the 
suspected animal.
One of the tests demonstrating the presence of EIAV in the blood 
of a horse is the horse inoculation tests and is carried out by 
injecting its blood into a susceptible horse. Development of disease 
in the recipient animal conclusively demonstrates the presence of the 
virus. However, the procedure is expensive and time consuming and, 
under the best circumstances, it is often difficult to interpret the 
clinical signs.
A number of serological tests have been used in research and in 
the diagnosis of EIA infection. These include complement fixation 
test (Kono and Kabayashi, 1966), serum neutralization test and agar 
gel immunodiffusion (AGID) test (Coggins et al., 1972; Roth et al., 
1971). The AGID test has been the most useful test in the diagnosis 
of EIA. It detects the presence of EIA specific antibody in the serum 
of the animal. It is reliable and reasonably sensitive. A 
correlation between precipitating antibody and EIA viremia has been 
demonstrated by Coggins et al. (1972). However, as with any 
serological test, the AGID test does not detect the phase of infection 
prior to antibody production.
More sensitive serological tests, such as radioimmunoassay 
(Coggins et al., 1978), immunofluorescence (Crawford et al., 1971) and 
enzyme linked immunoassay (Montelaro et al., 1982), have been utilized 
to detect EIAV antigen or antibody. They can aid in diagnosis in the 
cases in which AGID titers are extremely low.
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Prevention or treatment of EIA has not yet been successful 
because of our lack of understanding of the disease and the causative 
agent, EIAV, at the molecular level.
RETROVIRUSES
Although retroviruses have been isolated from a diverse group of 
animals and can produce a vast array of pathological consequences 
through a variety of mechanisms resulting in oncogenic as well as 
nononcogenic diseases, they have several characteristics in common. 
These include the nature of their genomes, their means of entering
cells, their composition and structure, and their mode of replication
via a DNA-intermediate. The last property distinguishes this class of 
viruses from other RNA viruses. As a result, viruses that use 
virus-coded, RNA-directed DNA polymerases to replicate their RNA 
genomes are grouped together as "retroviruses". The common taxonomic
features of Retroviridae are summarized in Table 1-1.
Morphological Features
The structure of retroviruses has been investigated by electron 
microscopy (Gross, 1970; Vigier, 1970). Most retroviruses are roughly 
spherical, about 100 nm in diameter (Bernhard et al., 1958). They 
comprise a core enclosed in an outer envelope made of a unit membrane, 
with spikes and knobs projecting from the outer surfaces (Figure 1-1). 
These spikes/knobs are made of glycoproteins (Rifkin and Compans, 
1971). By virtue of their morphology, as revealed in the electron 
micrographs, retroviruses can be classified into four categories: 
A-type, B-type, C-type and D-type particles (Bernhard, 1960; Fine and 
Schochetman, 1978; Sarkar et al., 1972).









Spherical enveloped virions (80-120 nm diameter), 
variable surface projections (8 nm), icosahedral 
capsid containing a ribonucleoprotein complex
Density 1.16 to 1.18 g/ml in sucrose, 1.16 to 
1.21 g/ml in cesium chloride, sensitive to lipid 
solvents, detergents, and heat inactivation (56°C,
30 min); highly resistant to UV and X-radiation
Linear positive-sense single-stranded RNA (60 S-70 S) 
composed of 2 identical subunits (30 S-35 S); 5' cap 
(M^G^ppp^NpNp); polyadenylated 3' end; 1% by weight
About 60% by weight; gag, internal structural proteins 
(4-5); pol, reverse transcriptase (1-2); env, envelope 
proteins (1-2)
About 35% by weight; derived from cell membrane 
About 4% by weight, associated with env proteins
+ Teich (1982)
* The figures in the brackets indicate numbers of polypeptides.
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A-type particles occur as intracellular forms only and do not 
have any infectivity. They are 60-90 nm in diameter, with an 
electron-luscent center surrounded by a double shell.
B-type particles have two distinguishing morphological features. 
First, long spikes are seen on the cell surface at budding site with 
doughnut-shaped cores, 75 nm in diameter, underneath. Second, after 
budding, the mature particles contain electron-dense nucleoids that 
are eccentrically located within the enveloped particle. The 
prototype member of the B-type particles is mouse mammary tumor virus 
(MMTV) (Table 1-1).
A key feature of C-type viruses is the absence of 
intracytoplasmic viral structures until budding has commenced at the 
plasma membrane. Crescent-shaped electron dense cores are seen at the 
plasma membrane at specific sites. Spikes of the virion envelope can 
also be seen. As virus maturation proceeds, the core eventually 
develops into a sphere with an electron-luscent center, and the cell 
membrane begins to pinch off as it surrounds this structure. Finally, 
extracellular forms with centrally located electron-luscent (immature) 
or electron-dense (mature) cores are observed. The majority of 
retroviruses isolated to date are of the C-type morphology including 
oncornaviruses.
D-type particles are associated with both intracellular and 
extracellular forms. Intracellular particles are ring-shaped,
60-95 nm in diameter, and are generally most abundant near the plasma 
membrane (Immature D-type particles). Mature D-particles are 
100-120 nm in diameter and have an electron-dense core that is
8
eccentrically located (Manning and Hackett, 1972). The virus 
classified in this class is Mason-Pfizer monkey virus (MPMV).
Subfamilies
The family Retroviridae has been classified further into three 
subfamilies, namely, oncovirinae, lentivirinae and spumavirinae. The 
main criteria for this classification have been cross-reacting 
group-specific major antigen within the subfamily and the 
characteristic disease the virus causes in an infected animal.
Oncovirinae includes the oncogenic and related nononcogenic 
retroviruses, the isolates that are difficult to classify in a 
retrovirus subfamily, and the noninfectious retrovirus-like particles.
Lentiviruses are viruses which cause slow infections, 
characterized by a prolonged incubation period and a protracted 
symptomatic disease phase. The diseases caused by lentiviruses in 
sheep are chronic pneumonia, maedi (shortness of breath) and visna 
(wasting due to progressive neurological impairment, with inflammation 
of central nervous system). The subfamily consists of one isolate 
from goats (caprine encephalitis arthritis virus) and several isolates 
from sheep, including visna, maedi, and progressive pneumonia virus 
(PPV). Because of the chronic nature of EIAV-induced disease, EIAV is 
often considered a lentivirus, however the absence of antigenic 
relatedness to visna virus (Stowring et al., 1979) does not 
substantiate this classification.
Spumaviruses or foamy viruses have been isolated from a number of 
mammalian species, including man, and establish persistent infections 
without evidence of pathogenesis. These viruses induce a 
characteristic spontaneous foamy degeneration of cells after a few
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weeks in culture. They share the common features of retroviruses. 
Typical spumaviruses are simian foamy virus (SFV) (Rabin et al., 1976) 
and bovine syncytial virus (BSV) (Malmquist et al., 1969).
Properties of type-C Onconaviruses
Biochemical and serological properties of type-C oncornavirus 
structural components have been reviewed recently (Montelaro and 
Bolognesi, 1980; Schafer and Bolognesi, 1977). Common general 
features of the structural proteins of type-C viruses are discussed 
here for the purpose of subsequent comparison with polypeptides of 
EIAV and other lentiviruses.
The spikes and knobs observed on the lipid envelope of the virion 
are composed of one or two glycoproteins and one or none 
nonglycosylated proteins coded by the env gene of the virus genome 
(Figure 1-1).
Underneath the lipid envelope is the inner coat structure 
containing a single polypeptide, which is usually phosphorylated. The
inner coat surrounds the icosahedral core, which is made up of at 
least two major structural proteins. Inside the icosahedral core is a
viral RNA genome in helical form with associated reverse transcriptase 
molecules and a very basic structural polypeptide. These inner 
structural polypeptides are coded by the gag gene and are group 
specific or type specific antigens.
Thus, analyses of oncornavirus proteins have consistently led to 
the identification of four or five small nonglycosylated polypeptides 
with molecular weight ranging from 10,000 to 30,000 daltons, and one 
or two larger glycoproteins.
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Figure I—1: A model of retroviruses indicating the structural
components. KN = knob, VM = viral membrane, IC = inner coat, 




Friend murine leukemia virus (FLV) and Rous sarcoma virus (RSV) 
are prototype-C oncornaviruses representing mammalian and avian type-C 
viruses, respectively. Morphologically these viruses are quite 
similar and have analogous structural components (Montelaro and 
Bolognesi, 1980). The polypeptide compositions of FLV and RSV were 
determined using high resolution sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) and guanidine 
hydrochloride-gel filtration (GHC1-GF) (Montelaro et al., 1978). 
Qualitative and quantitative properties of the virion structural 
components and their position in the intact virion, deduced from 
localization experiments described below, are summarized in Table 1-2.
Localization of Structural Polypeptides
Virion polypeptides can be assigned to certain site(s) in the 
intact virus particle and in relation to each other by a variety of 
direct and indirect techniques. These include differential labeling, 
protease treatment, preparation of viral substructures and use of 
cross linking reagents.
The surface proteins comprising the spikes and the knobs of the 
virion can be specifically radioiodinated using lactoperoxidase 
(Cheevers et al., 1980; David and Reisfield, 1974; Phillips and 
Morrison, 1971) or can be removed on careful digestion of the whole 
particles with protease (Mosser et al., 1977; Montelaro et al., 1982). 
They constitute the surface knobs and spikes, visible in the electron 
micrographs and are responsible for many biological properties of the 
viruses (Schafer and Bolognesi, 1977), including host cell specificity 
and induction of neutralizing antibody. The knob structure is
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Table 1-2: Structural components of avian and murine type-C
retroviruses
Virion polypeptide 
Avian Murine Structural component Virion structure
gp85(ll%) gp71(10%) Knob
gp35(9%) pl5E(2%) Spike ► Envelope
pl0(5%) pl2E(13%) Envelope associated
pP19(ll%) ppl2(7%) inner coat inner coat
p27(36%) p30(50%) core shell core
pl5(13%) pl5C(13%) core associated exterior
pl2(13%) pl0(4%) nucleoprotein Ribonucleo-
p91(8)(1%) p70(a)(1%) reverse transcriptase protein
p64(a)(1%) complex
Montelaro and Bolognesi (1980).
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believed to be composed of the hydrophilic envelope glycoprotein (gp85 
or gp71), while the spike contains the hydrophobic envelope proteins,
like avian gp35 and murine pl5E, which are believed to span the lipid
bilayer. These latter proteins aggregate in 6 M guanidine 
hydrochloride and require detergents to keep them in solution 
(Montelaro et al., 1978). These surface knob and spike components may 
or may not be linked by intermolecular disulfide linkages depending on 
the individual virus studied.
The retroviral particles can be partially disrupted, using 
controlled concentrations of nonionic detergents (Coffin and Temin, 
1971; Davis and Rueckert, 1972; Teramoto et al., 1977) to generate 
subviral particles. Polypeptide analysis of subviral particles on 
SDS-PAGE and electron microscopic observation can allow an assignment 
of the polypeptide to the different structural features of the virion.
Mild detergent treatment of retroviruses releases core structures
that band in equilibrium sucrose gradients at a density of
approximately 1.24-1.26 g/ml, compared with intact virions that band 
at 1.16-1.18 g/ml (Teramoto et al., 1977). The increase in density is 
due to the solubilization of the lipid containing envelope and to 
release of the internal core structure. Electron microscopic studies 
on virus and core structures show that the murine C-type cores possess 
icosahedral symmetry (Nermut et al., 1972; Schafer and Bolognesi,
1977). SDS-PAGE analysis of the cores show that they contain the most 
abundant nonglycosylated polypeptide found in virions (usually with a 
molecular weight of 24,000-30,000 daltons) and a smaller, highly basic 
polypeptide.
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Further detergent treatment of the cores releases the genomic RNA 
associated with the basic polypeptide (Bolognesi, 1973; Davis and 
Rueckert, 1972) and reverse transcriptase. In avian viruses, the 
basic component is designated as pl2 and, in murine viruses, plO 
(Bolognesi, 1974).
Electron microscopic investigations with murine and avian type-C 
viruses (Frank et al., 1978) revealed the presence of a thin layer, 
designated the inner coat, located just beneath the viral envelope as 
demonstrated in the virus model (Figure 1-1). Analogous major 
phosphoproteins, ppl9 in avian and ppl2 in murine viruses, are 
believed to comprise the inner coat structure. These phosphoproteins 
are neither present in purified virus core nor detectable on the virus 
surface (Schafer and Bolognesi, 1977). Also in avian viruses ppl9 
could be cross-linked to gp35 when intact virions were treated with 
reversible cross-linking reagnets. The phosphoproteins are the most 
type specific antigens of the respective viruses (Bolognesi et al., 
1975; Hunsmann et al., 1976; Schwarz et al., 1976) and exist in 
phosphorylated as well as nonphosphorylated forms (Erickson et al., 
1977; Lai, 1976; Pal and Roy-Burman, 1975; Sen et al., 1976, 1977). 
They also have the affinity for the homologous viral RNA (Leis et al., 
1978; Sen et al., 1976, 1977; Sen and Todaro, 1977).
Replication of Retroviruses
Retroviruses are unified by the manner in which their genomes are 
replicated during infection. In its simplest form, replication can be 
envisioned as
RNA DNA -> RNA
with the first step mediated by a virus-coded, RNA-directed DNA
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polymerase (reverse transcriptase) carried in the infectious 
particles, and the latter step mediated principally by host enzymes, 
also responsible for expression of cellular genes.
Retroviruses usually associate stably with the cells they infect. 
This is accomplished by covalent integration of retroviral DNA copy 
into the chromosomal DNA of host cells. Intermediate proviral DNA 
molecules synthesized from viral RNA are partial double stranded 
linear DNA, closed circular molecules and finally, the integrated 
provirus (Coffin, 1979). A simplified schematic view of the major 
events in the replication of a retrovirus are presented in Figure 1-2 
(Varmus and Swanstrom, 1982). Transcription of proviral DNA results 
in the synthesis of at least two types of mRNA, a larger one serves as 
a message for gag and pol gene products while the smaller mRNA codes 
for env proteins. The large RNA species is also the viral genome 
which is packaged into the virus.
EQUINE INFECTIOUS ANEMIA VIRUS
As mentioned before, EIA is one of the first diseases shown to 
have a viral ("filtrable") etiology. The wide range of pathogenic 
properties of this disase can be attributed to single retrovirus, 
called the equine infectious anemia virus (EIAV). Apparently, the 
infected animal mounts an immune response against the invading virus, 
usually 16-42 days post-infection. However, it does not eliminate the 
virus completely. Once infected, the virus persists in the host.
Some animals experience periodic bursts of viremia at unpredictable 
intervals (Kono et al., 1973; Orrego et al., 1982), and they are 
usually associated with characteristic symptoms of EIA described 
earlier. Such a periodic disease process is unique among retrovirus
16
Figure 1-2: A simplified representation of replication of retrovirus
genome. 1. Viral RNA; = 5' and 31 terminal repeats;
= 5' and 3' untranslated regions; PB = primer binding site; G,P, 
and E = gag, pol, and env genes, respectively. 2 and 3. cDNA 
and double stranded DNA synthesis. 4. Circular double stranded 
viral DNA. 5. Integration of viral DNA into host genome. 6. 
Transcription of proviral DNA to yield mRNAs and viral RNAs.
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infections and raises a number of intriguing questions concerning the 
molecular biology of EIAV.
The most important problems posed by EIAV are a) why is the 
clinical disease and bursts of viremia periodic and b) where and how 
does the virus persist in the presence of an apparently active immune 
response? Both of these questions must be viewed in the light of our 
knowledge about other retroviruses, but they also require an 
understanding of the unique biochemical and immunological properties 
of EIAV.
Growth Characteristics
Whereas the clinical and epidemiological aspects of EIA have been 
exhaustively dealt with and amply reviewed (Crawford et al., 1978; 
McGuire and Henson, 1973), knowledge of the molecular biology of EIAV 
had been slow due to the lack of a suitable tissue culture system for 
obtaining the virus in the quantities required for characterization. 
EIAV multiplication was apparently restricted in cells’cultured in 
vitro, with the exception of equine leukocyte cultures (Kabayashi and 
Kono, 1967). However, the lack of a convenient method of measuring 
the virus propagation in these cultures and the presence of high 
concentration of serum required for growth and maintenance of 
leukocyte cultures complicated the purification of EIAV. EIAV strains 
have recently been selected for replication in equine fibroblast 
cultures without cytopathic effects (Kono and Yoshino, 1974; Malmquist 
et al., 1973). These laboratory strains now permit cultivation, 
propagation and purification of EIAV in quantities sufficient for 
biochemical and immunological analysis. That these laboratory strains 
are representative isolates of EIAV is indicated by the facts that
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they retain their virulence for horses after greater than 50 passages 
in equine fibroblasts, and retain their ability to replicate in equine 
fibroblasts in vitro after 3 clinical cycles in vivo (Crawford et al., 
1978). The isolate of EIAV described by Malmquist et al. (1973) grows 
in monolayer cultures of an equine dermal cell line and primary equine 
embryonic spleen. Subsequently, they precipitated the virus from 
culture fluids with polyethylene glycol, removed the viral lipid with 
ether, and assayed the antigen using a radial immuno-diffusion 
technique. It has since been noted (Matheka et al., 1976) that the 
virus, adapted by Malmquist and coworkers to grow in equine dermal 
cells and fetal spleen, propagates equally well in other equine tissue 
culture systems, including primary equine fetal lung and kidney cell 
cultures.
In vitro and in vivo Replication of EIAV
The cell adapted strain of Malmquist et al. (1973) has been 
routinely grown in tissue culture systems by a number of workers for 
biochemical characterization (Cheevers et al., 1976; Matheka et al., 
1977; Sentsui and Kono, 1981) and morphological studies (Matheka et 
al., 1976; Weiland et al., 1977). Anderson et al. (1979) 
characterized the in vitro infection of equine dermal fibroblasts and 
demonstrated that the cells persistently infected with EIAV show no 
alterations in cell morphology or growth kinetics when compared to 
uninfected cells. The production of extracellular virus was shown to 
be uniform throughout the cell cycle. Also the normal levels of 
progeny virus were produced in cultures treated with mitomycin C (DNA 
synthesis inhibitor) and placed in serum-containing medium. This was 
in contrast to oncornaviruses which require that host cells pass
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through at least one cell cycle to initiate viral RNA synthesis and 
subsequent virus production (Bader, 1975; Fischinger et al., 1975; 
Paskind et al., 1975). These results suggest that either the 
integration of EIA proviral DNA is independent of host DNA synthesis 
or the integration of provirus, which does occur in equine dermal 
(Crawford et al., 1978) and kidney (Rice et al., 1978) fibroblasts, is 
not a prerequisite to replication. An independence of viral 
replication and host cell DNA synthesis, if true, is one of the 
characteristics that EIAV shares with visna virus, a lentivirus 
(Thormar, 1976), a relationship that may carry important pathogenic 
implications.
In contrast to the restrictive host range iri vitro, after 
inoculation of EIAV in a pony, there is rapid virus proliferation to 
high titers in practically all tissues (Kono et al., 1971). Most of 
the infectivity in the plasma is in the form of infectious 
virus-antibody complexes (Henson and McGuire, 1974). Between febrile 
episodes, infectivity declines in both serum and tissues, the liver 
and spleen retaining higher titers than other organs.
Proviral DNA of EIAV
The persistent nonlytic infection of equine fibroblasts with EIAV 
is maintained by the integration of proviral DNA into the cellular 
genome (Crawford et al., 1978; Rice et al., 1978) which could be 
detected by reassociation study with cDNA synthesized from the viral 
RNA. This revealed an average of two to six viral DNA copies per 
haploid genome (Cheevers et al., 1982; Rice et al., 1978). There was 
no detectable hybridization of EIAV cDNA with normal horse DNA, 
showing that it is not an endogenous virus of the horse. Sequences
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related to EIAV were neither found in DNA of other Equus species, nor 
in a variety of other mammals. Also EIAV cDNA did not hybridize with 
a variety of other retroviruses, thus showing no sequence homology.
Morphological and Physicochemical Characteristics
EIAV has been classified as a member of the family Retroviridae 
(Charman et al., 1976) because of morphological features and 
biochemical properties it shares with other retroviruses. Studies on 
EIAV indicate that the particles have a buoyant density of 
1.15-1.16 g/ml at 20°C. (Charman et al., 1976; Matheka et al., 1976; 
Sentsui and Kono, 1981) and the sedimentation constant, S2Q w» for the 
virus averages 656 ± 5S. Morphologically, particles are 80-120 nm in 
diameter with a very flexible but usually spherical shape (Matheka et 
al., 1976; Teich, 1982; Weiland et al., 1977). Inside the particles 
are pleomorphic, spherical or rod-shaped electron dense nucleoid,
40-60 nm in diameter or length. Thin surface projections or knobs 
have been observed on the outside, and sometimes an inner shell around 
the core is seen (inner coat). EIAV buds from the plasma membrane 
following the appearance of a crescent-shaped nucleoid under the 
plasma membrane, typical of C-type particles. Thus, EIAV displays a 
complex morphology characteristic of type-C viruses (Gonda et al.,
1978).
EIAV also shares other characteristics with the retroviruses. 
These include sensitivity to ether (Nakajima and Obara, 1964), 
sensitivity to IdU during the early stages of replication (Kono et 
al., 1970), 60-70 S RNA genome (Charman et al., 1976; Cheevers et al.,
1977) made of two identical single stranded 34S subunits and a reverse
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transcriptase enzyme associated with the virions (Charman et al.,
1976; Cheevers et al., 1978).
EIAV is a non-oncogenic virus and has epidemiological 
similarities to the viruses of slow infections, lentiviruses.
However, the genomic and serological unrelatedness to either 
oncoviruses or lentiviruses has not permitted further definitive 
classification of EIAV into a retrovirus subfamily.
Structural Components of EIAV
A prerequisite to the detailed study of any virus and associated 
disease is the knowledge of the structural components of the virus. 
EIAV is a retrovirus with protein, lipid and nucleic acid content 
typical of other retroviruses. Proteins comprise about 60% of the 
virion mass and are important components for structural and functional 
reasons. Immune responses of the animal are directed against these 
proteins. A thorough description of the major antigens of EIAV is 
fundamental to understanding the dynamic interaction between host 
immune mechanism and the virus antigens. However, prior to this 
study, little definitive work was available on the structural 
polypeptides of EIAV.
Since serological comparisons have failed to detect any 
relatedness between EIAV and a number of other retroviruses (Charman 
et al., 1976; Stowering et al., 1979), this has led to the suggestion 
that the polypeptide composition of EIAV may be distinct from type-C 
retroviruses (Charman et al., 1976; Rice et al., 1978). Preliminary 
descriptions of EIAV polypeptide composition have been contradictory 
and thus have been unable to resolve the exact relationship of EIAV to 
other retroviruses.
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The major nonglycosylated protein of EIAV, which is employed in 
standard immunodiagnostic tests, is apparently a group specific 
antigen with a molecular weight of 25,000-29,000 (Barta and Issel, 
1978; Cheevers et al., 1977; Ishizaki et al., 1976) although one 
report claims a molecular weight of only 7,600 (Hart et al., 1976). 
Cheevers et al. (1978) reported further that 80% EIAV structural 
protein is accounted for by five polypeptides, including two 
nonglycosylated components (p29 and pl3) which comprise one-half of 
the virion protein and three glycoproteins (gp77/79, gp64 and gp40). 
They also describe eight or nine minor polypeptides of unknown 
significance. Ishizaki et al., (1978) detected three major 
nonglycosylated proteins (p25, pl4 and pll), but only two 
glycoproteins (gp80 and gp40). While both of the above investigators 
employed SDS-PAGE as the sole analytical procedure, Charman et al. 
(1979) used isoelectric focussing to detect four major nonglycosylated 
components [p25, pl2, plO (acidic) and plO (basic)], but made no 
statements concerning virion glycoproteins. Thus the exact 
polypeptide composition of EIAV, and the relationship of the 
polypeptides to each other and to analogous polypeptides of other 
retroviruses remains to be determined.
ANTIGENIC VARIATION
An invading organism, as a result of multiplication in the host, 
induces the host to elicit an immune response. A strong immune 
response, normally, will eliminate the invading organism and thus cure 
the host. However, successful parasites have devised ways to evade 
the host immunosurveillance system and survive.
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The host elicits a neutralizing antibody directed against 
antigens responsible for infectivity. Usually these antigens are 
located on the surface. In the case of viruses these surface antigens 
or proteins are important for cell recognition, attachment and 
infection. A parasite that can vary its surface antigens, at a 
sufficient rate, will present itself in a form new to the host and 
will not be eliminated. This type of phenomenon involving alterations 
in structural antigens of the parasite during replication in an animal 
is called antigenic variation. Antigenic variations in surface 
components only are likely to benefit the parasite in its survival 
against the host immune response. Multiplication or replication of 
the parasite with altered surface antigen will then occur, until an 
effective host immune response against this strain ensues. Several 
parasites, including some protozoan and a few virus members of some 
families, undergo antigenic variation.
Trypanosomes
Trypanosomes are parasitic protozoa which cause sleeping sickness 
in man and animals, primarily in developing countries (Goodman, 1978; 
Walsh and Warren, 1979). These tsetse fly-transmitted parasites 
inhabit the blood stream and tissue spaces of their mammalian hosts, 
where they rapidly stimulate the production of trypanocidal antibody. 
Before all the trypanosomes can be eliminated, however, antigenically 
distinct variants appear in the bloodstream which perpetuate the 
infection, until they, in turn, are removed by the antibody. Usually, 
the trypanosomes can elude the immune system in this cycle, which 
leads eventually to the death of the host.
25
The antigenic profile of the trypanosome is governed by the 
structure of its surface coat. This coat is made up of a densely 
packed layer of glycoprotein molecules, the variant surface 
glycoproteins (VSGs), whose structure is unique for each variant 
antigen type. The genome contains more than 100 variant antigen genes 
probably generated by gene duplication and mutation (Englund et al., 
1982), and by controlling the expression of these genes, the 
trypanosome is able to parade a sequence of different variants past 
the immune system of the host.
Poliovirus
Antigenic variation has been observed in poliovirus, a 
picornavirus. The attenuation of neurovirulent poliovirus involves 
multiple variations in the single stranded RNA genome and in its gene 
products (Kew et al., 1980), resulting in nonvirulent oral 
poliovaccine strains. The currently used poliovaccine strains were 
selected as spontaneous mutants of wild isolates following multiple 
passages in simian extraneural cells and tissues (Sabin and Bougler, 
1973). The surfaces of wild type and attenuated viruses could be 
distinguished by serological tests (Van Wezel and Hazendonk, 1979). 
Structural alterations were detected in three of the four viral 
structural proteins, VP1, VP3, and VP4, and it was estimated that 1.5% 
of total amino acids were substituted in the course of attenuation 
leading to the vaccine strain.
Genetic changes observed here are essentially of the same nature 
that can also lead to a reversion of an attenuated, nonvirulent strain 
to a virulent one. Indeed, multiple genetic changes (>100) have been 
found to occur in the attenuated virus after the ingestion of oral
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poliovaccines and subsequent replication of virus in humans (Kew et 
al., 1981; Nottay et al., 1981). These virus isolates were recovered 
subsequent to the vaccine related cases of poliomyelitis. SDS-PAGE, 
peptide mapping and oligonucleotide mapping were used to detect 
changes in proteins and genomes, respectively. It was demonstrated 
that both the gene and gene products of poliovirus evolve at 
detectable rates during replication in humans. This is in sharp 
contrast to what happens during propogation in cell culture, where the 
RNA genome and the viral proteins are remarkably conserved. Obvious 
mediators for change in a virus population are antibodies. However, 
other factors must play a role, because changes in the virus 
polypeptides were not restricted to the virion structural proteins, 
where alterations might be expected to occur in response to antibody 
pressure, but were also found in the non-capsid proteins, which are 
thought to function only intracellularly (Kew et al., 1981).
Probably, the dynamics of selection are very complex because the virus 
population is highly mutable and the human population is 
immunologically heterogeneous.
In any case, the attenuated poliovirus undergoes genetic 
variation upon human intestinal passage and there is a potential for 
these viruses to revert to virulence as a result of multiple genetic 
variation.
Influenza Virus
In contrast to picornaviruses like poliovirus, which contain 
positive-strand single stranded RNA, influenza viruses contain a 
segmented negative-strand RNA genome. Influenza viruses are unique in 
their potential to cause epidemics and pandemics and are characterized
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by a high degree of genetic variability. These viruses are divided 
into three types, A, B and C, based on differences in their internal 
proteins. They also differ in their biological and epidemiological 
behaviour (Young et al., 1980). Most influenza cases in man are caused 
by type A viruses which are further divided into subtypes according to 
serological differences of their surface antigens, hemagglutinin (HA) 
and neuraminidase (NA). Although there are antigenic subtypes among 
other DNA and RNA viruses, these strain variants are rather stable in 
nature and there is no evidence of such constant modification of viral 
genome and viral proteins as it occurs among influenza viruses. Two 
types of antigenic variations are observed among these viruses, 
antigenic drift and antigenic shift.
Antigenic drift is a gradual change observed in the surface HA 
and NA proteins among the virus isolates and is caused by mutational 
changes in the viral genome leading to single amino acid changes (Both 
et al., 1980; Laver et al., 1980) and selective pressure from immunity 
in human populations. The drift is usually slow. In laboratory, 
variants were recovered from an infected animal and they were found to 
contain changes in peptide maps of the HA subunit (Laver and Webster,
1972).
Antigenic shift causes the advent of new pandemic viruses that 
are very different from the strains prevalent before or during the 
period the new virus emerged. These changes take place invariably in 
HA and sometimes also in NA antigen. The mechanism of the antigenic 
shift is not clearly understood. Two hypotheses have been proposed 
(Nayak, 1977).
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The direct mutation theory maintains that antigenic shift is an 
extension of antigenic drift in which accumulated mutation and 
selection pressure eventually produce a new strain different enough to 
cause a pandemic. However, the differences between strains 
responsible for subsequent pandemics are so numerous that it is 
difficult to visualize how the mutations could have taken place all at 
once.
The genetic recombination theory proposes that gross changes are 
caused by genetic exchange among influenza A viruses prevalent in 
nature. Since influenza viruses contain a segmented RNA genome, 
recombination may take place with high frequency following 
co-infection of a cell with two viruses. Such recombinants or hybrid 
viruses are produced by mixed infection in cell culture, in eggs as 
well as in animals (Webster, 1972). Also many of the viruses from 
different species share common antigens, indicating occurrence of 
recombination.
Visna Virus
Visna virus, a retrovirus, is the etiologic agent of an 
inflammatory and degenerative disease of the central nervous system of 
the sheep (Brahic and Haase, 1981; Hasse, 1975). The disease is 
characterized by a prolonged incubation period, followed by a subacute 
progression of symptoms to death. The unusual aspects of visna is the 
life-long persistence of the virus which undergoes progressive 
antigenic variation in a single infected animal (Narayan et al., 1977; 
Narayan et al., 1978). Biochemical characterizations of such variants 
recovered from a sheep revealed alterations in the genome when 
examined by oligonucleotide mapping to separate RNase T1 resistant
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fragments (Clements et al., 1S80). Alterations in the genome were 
localized near the 3' end, presumably in the gene coding for envelope 
products. The structural alterations in the envelope glycoprotein, 
gpl35, could be detected by two dimensional peptide mapping, while the
internal proteins were found to be conserved (Scott et al., 1979). By
altering the envelope glycoprotein, visna virus is believed to evade 
the host immunosurveillance system. However, recently Thormar et al. 
(1983) reported the presence of originally inoculated virus in the
experimentally infected animal, long after inoculation, and thus
questioned the importance of antigenic variation in visna.
The Case for Antigenic Variation in EIAV
The periodic nature of equine infectious anemia (EIA) has been 
observed by several investigators (Kono et al., 1971; Kono et al.,
1973) and recently these observations were confirmed by Orrego et al. 
(1982). Horses experimentally inoculated with a "cloned" virus 
exhibited a chronic disease with periodic relapses of fever and 
associated viremia. Kono and coworkers (1973) recovered virus 
isolates during successive febrile episodes and carried out serum 
neutralization assays demonstrating that virus isolates were not 
susceptible to previously formed neutralizing antibodies but reacted 
with antibodies produced some weeks later. Also the late isolates 
differed from one another when examined in cross-neutralization tests. 
Immune sera used did not have high specificity for a particular virus, 
but this may not be surprising considering the presence of some common 
antigenic determinant and the heterogeneous immune response of the 
host. The results did strongly indicate that occurrence of virus 
variants in vivo as the most likely explanation for their resistance
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to heterologous antisera. Moreover, these isolates were found to be 
genetically stable upon tissue culture passages.
The variants could be differentiated from one another by 
neutralizing antibodies, but not by complement fixing and 
precipitating antibodies (Kono et al., 1971). These results suggest 
that the differences among the variants are in their surface antigens. 
Since the host elicits neutralizing antibody against these surface 
antigens, the structural alterations in these molecules can have 
significance with regards to antigenic variation in EIAV.
A model for the chain of events following infection of a horse 
with EIAV is presented in Figure 1-3. This antigenic variation 
appears to play a crucial role in the establishment of a persistent 
infection and also presents a major obstacle in developing a 
vaccination protocol for this economically important disease.
RESEARCH OBJECTIVES
The epidemiology of the EIA is very interesting as demonstrated 
by its unpredictable periodic occurrence and associated bursts of 
viremia. An apparent breakdown of the control mechanisms which 
suppress virus replication between the cycles allows a resurgent 
viremia. This outpouring of virus and associated antigens in the face 
of a vigorous immune response sets in motion a series of 
immunopathologic events that cause the clinical signs and the lesions 
of EIAV. Several questions remain unanswered concerning the mechanism 
of the disease and the molecular biology of EIAV. The present 
investigation has attempted to answer some of the questions regarding 
the molecular biology of EIAV, and these are listed below along with 
their significance.
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TI ME
Figure 1-3: A schematic view of the sequence of events in an animal
suffering with chronic EIA.
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a. What is the polypeptide composition of EIAV? Is it unique and 
distinct from the polypeptide composition of other retroviruses which 
apparently do not undergo antigenic variation during replication in a 
single animal? These studies were designed to provide a definitive 
analysis of EIAV protein composition and to form a basis for further 
study of EIAV antigens.
b. What are the properties of structural polypeptides of EIAV and how 
are these polypeptides related to each other and to the polypeptides 
of other retroviruses? The answers to these questions would establish 
the relationship of polypeptides, and help to understand the functions 
of these components.
c. How are these polypeptides organized in the intact virion? The 
knowledge of the polypeptide organization in EIAV would enable us to 
compare EIAV with the current retrovirus model and help focus our 
attention on polypeptides which could be important for antigenic 
variation.
d. What is the biochemical nature of antigenic variation? This 
question is fundamental to understanding the existence of variants in 
a single animal and the role of antigenic variation in virus 
persistence.
No vaccine protection is available yet against this economically 
important disease because we do not know enough about the EIAV 
antigens and the mechanism of antigenic variation. It is hoped that 
the investigation carried out here will bring research closer to 
development of a vaccine against EIAV and will also further our 




A list of chemicals used throughout this study, including 
abbreviations and sources of supply, is shown below.
acetic acid - Mallinckrodt, Inc.; acetone - MCB; acrylamide - 
Biorad; ammonium bicarbonate - Sigma; ammonium persulfate - MCB; 
ampholite (pH 3-10) - LKB; autofluor - National Diagnostics; blue 
dextran - Sigma; bovine serum albumin, crystalline (BSA) - Sigma; 
bromelain, pineapple, grade II - Sigma; bromophenol blue - Sigma; 
n-butanol - Baker; cellulose coated thin layer plates, 20 x 20 cm - EM 
Lab; chloramine-T - Sigma; p-chloromercuriphenylsulfonate - Sigma; 
chymotrypsin - Sigma; coomasie brilliant blue - Sigma; 7-deoxycholate 
(sodium salt) (DOC) - Sigma; 2,4-dinitrophenyl alanine (DNP-alanine) - 
Sigma; diphenyl carbamyl chloride treated-trypsin (DPCC-trypsin) - 
Sigma; Eagle's minimal essential medium (MEM) - GIBCO Lab.; 
ethylenediamine - Sigma; ethylene dinitrilo tetraacetic acid (EDTA) - 
MCB; fetal calf serum - GIBCO Lab.; formic acid -MCB/Baker; guanidine
3- Sigma; [ H]-glucosamine - NEN; glycine - Sigma; glycerol - J.T. 
Baker; hydrochloric acid - MCB; hydrogen peroxide - Sigma; isopropanol
- MCB; lactoperoxidase - Calbiochem; lentil lectin Sepharose 4B -
1A 3Pharmacia; [ C]-leucine - NEN; [ H]-leucine - NEN; 2-mercaptoethanol
- Eastman; 3-mercaptopropionate - Sigma; methanol - Mallinckrodt;
N,N'-methylene bisacrylamide - Biorad; new born calf serum - GIBCO
Lab.; nonidet P-40 (NP-40) - Particle Data Laboratories, Ltd.;
32penicillin G - Sigma; phosphoric acid - MCB; P-phosphoric acid -
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ICN; pyridine - Mallinckrodt, Inc.; Sepharose 6B - Pharmacia; sodium 
azide - MCB; sodium bicarbonate - Sigma; sodium chloride - 
Mallinckrodt, Inc.; sodium dodecyl sulfate (SDS) - Biorad; sodium
hydroxide - J.T. Baker; sodium iodide - Mallinckrodt, Inc.;
125 125I-sodium iodide ( I) - NEN; sodium metabisulfite - MCB; sodium
phosphate, dibasic - Sigma; sodium phosphate, monobasic - Sigma;
streptomycin sulfate - Sigma; sucrose - MCB; N,N,N',N'-tetramethylene
diamine (TEMED) - Biorad; trichloroacetic acid (TCA) - MCB;
tris(hydroxymethyl) aminomethane (Tris) - Sigma; Urea - Sigma; V8
protease (Staphyloccoccus aureus) - Miles Lab.
Virus Propagation and Purification
The cell-adapted Wyoming strain (Malmquist et al., 1973) of EIAV 
was propagated in primary equine fetal kidney cells maintained in 
Eagle's minimal essential medium (MEM) supplemented with 4 to 10% 
sterile newborn or fetal calf serum, 25 mM HEPES buffer, 10 mM sodium 
bicarbonate, 150 U of penicillin G per ml, and 150 yg of streptomycin 
sulfate per ml (Amborski et al., 1979). Persistently infected 
cultures were maintained in roller bottle cultures containing 50 ml of 
medium. Under these conditions virus production continued for 
approximately 3 months, until cell senescence.
Supernatant medium was harvested every 3 to 4 days for virus 
purification. After the cell debris was removed from the medium by 
centrifugation at 8000 rpm for 30 min in a Sorvall GSA rotor 
(8500 x g), the virus containing supernatant was concentrated about 
10- to 40-fold by using a Pellicon membrane filter cassette system 
(nominal exclusion 10^ daltons molecular weight) (Millipore Corp., 
Bedford, Mass.). The virus concentrate was then layered over a 10-ml
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cushion of 10% sucrose, and the virus was pelleted by centrifugation 
in a type 19 rotor at 19,000 rpm (50,000 x g) for 2 h. The pelleted 
virus was suspended in 10 mM sodium phosphate buffer, pH 7.2 and 
sedimented to its equilibrium density (1.18 g/ml) on 30 ml 20 to 80% 
(v/v) glycerol gradients in a Beckman SW28 rotor centrifuged at
28,000 rpm (130,000 x g) for 3 h. All procedures were carried out at 
4°C. After the run, the virus band was withdrawn with a syringe.
With these procedures, about 10 mg of EIAV (estimated as protein, 
Lowry et al., 1951) could be purified per week from 10 roller bottles 
yielding one liter of tissue culture fluid (Montelaro et al., 1982).
Virus Isolates
For biochemical comparisons, EIAV isolates were obtained by 
serial passage of the Wyoming strain of EIAV in Shetland ponies 
(Orrego et al., 1982). Isolates recovered were designated by passage 
and isolate number. For example, isolate Pl-1 was recovered from 
plasma of a first-passaged pony (No. 47), two weeks after the 
inoculation when the pony became AGID test positive. Isolates P2-1 
and P2-6 were obtained from plasma samples of a second-passaged pony 
(No. 82) during the first and sixth febrile episodes, respectively. 
Isolates P3-1 and P3-3 were obtained from plasma samples of a 
third-passaged pony (No. 127) during first and third febrile episodes, 
respectively (Figure II-l and Figure 111-13).
For the biochemical studies presented here, the viruses recovered 
from end-point dilutions of respective plasma samples were propagated 








Figure II-l: Scheme indicating the generation of EIAV isolates in
experimentally inoculated ponies.
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Radioactive Labeling of EIAV in Vivo
a. [3H]-leucine or [^C]-leucine-EIAV
Infected fetal equine kidney cells in falcon flasks were 
transferred overnight to leucine-free medium. Radioactively labeled 
EIAV was propagated in leucine-free medium containing 25 pCi/ml of 
[3H]-leucine or 2.5 pCi/ml of [^C]-leucine.
3b. [ H]-glucosamine-EIAV
Infected fetal equine kidney cells were transferred overnight to 
medium reduced to l/10th the normal glucose concentration.
3[ H]-glucosamine-EIAV was propagated in the same medium supplemented
3with 25 pCi/ml of [ H]-glucosamine.
c. [32P]-EIAV
32The virus was labeled with [ P] as described by Pal et al. 
(1975). Briefly, the labeling was carried out by growing the infected 
fetal equine kidney cell monolayers in 50% phosphate-free MEM 
supplemented with 10% dialyzed fetal calf serum and 100 pCi/ml of 
[32P].
After 24 h intervals of growth in the appropriate radioactive 
medium, the virus containing media were centrifuged to remove the 
cellular debris, and the virus was purified from the supernatant fluid 
by centrifugation procedures essentially as described before 
(Montelaro et al., 1978).
Radioactive Labeling of the Virus or the Virus Components in Vitro 
125a. I-surface labeling of EIAV using lactoperoxidase
Procedures for surface specific radioiodination using 
lactoperoxidase have been described (Phillips and Morrison, 1971;
David and Reisfield, 1974). About 40-75 pg of purified unlabeled EIAV
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was suspended in 0.5 ml of PBS-A, pH 7.2 and the following were added
125in the given order: 1 mCi of 1(20 yl), and 1 unit of
lactoperoxidase (50 units/ml in PBS-A). The reaction was initiated by
—2 —2 addition of 10 yl of ^©£(10 M). Three subsequent additions of 10 M
^2^2 were ma(*e at 5 min intervals. At the end of a 20 min period, the
reaction was terminated by adding 1.4 ml of PBI containing 0.02%
sodium azide. The diluted reaction mixture was then layered onto a
glycerol step gradient (20%:80%::2ml:lml) and centrifuged at
30,000 rpm (100,000 x g) for 60 min at 4°C in a SW50.1 rotor. The
gradient was then fractionated into BSA-coated plastic beakers, and
5 yl from each fraction was counted for radioactivity in a Packard
125gamma counter. Fractions containing I-labeled EIAV were pooled,
diluted with 0.01 M phosphate buffer and pelleted by centrifugation in
SW50.1 rotor at 45,000 rpm (240,000 xg) for 45 min. The pellet was
suspended in cold 0.01 M phosphate buffer, pH 7.2 and stored at -80°C. 
125b. I-labeling of virus polypeptides using chloramine-T (Hunter,
1978).
The following solutions were prepared fresh in 0.05 M sodium
phosphate buffer, pH 7.4: chloramine-T, 0.4%; sodium metabisulfite,
0.25%; and sodium iodide, 1%. To a 10 x 75 mm test tube, 25-50 yg of
protein solution was added, followed by 0.05 M phosphate buffer,
125pH 7.4 to a volume of 200 yl and 1 mCi of I (20 yl). The
iodination was initiated by addition of 25 yl of chloramine-T. The
reaction was allowed to proceed for 60 sec and then terminated by
adding 100 yl of sodium metabisulfite. To minimize the noncovalent 
125binding of I to proteins, 200 yl of carrier sodium iodide solution 
was added and mixed well.
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125Unreacted I was separated from radiolabeled protein using a
column (0.8 x 22 cm) of Sephadex G-25 prepared in a disposable 10 ml
pipet and eluted with PBS-A.
125c. I-labeling of polypeptides in gel slices using chloramine-T.
For certain purposes (e.g. peptide mapping), it was convenient to
radioiodinate proteins contained in gel slices after SDS-PAGE
separation (see below). The method has been described by Elder et al.
(1977b), and adapted as follows. Protein bands were detected by
staining with 0.25% Commassie brilliant blue for 30 min, followed by
destaining in 7.5% acetic acid (v/v) and 25% methanol (v/v). The
protein bands of interest were then excised from gel with a clean
scalpel. Gel slices, contained in perforated wells of a microliter
plate, were washed with 25% isopropanol for 4 to 6 h and then with 10%
methanol overnight to remove SDS and other contaminants. The gel
slices were then placed in siliconized tubes and dried under a heat
125lamp and vacuum. The proteins were radioiodinated with I in the
dried gel slices by a modification of the chloramine-T method
(Greenwood et al., 1963). The following components were added to each
125tube containing the dried gel slice: 1 mCi of I (20 pi), 50 yl of
0.5 M sodium phosphate buffer, pH 7.5 and, finally, 10 yl of
chloramine-T solution (0.5%) in phosphate buffer. After a 30 min
reaction time, the labeling was stopped by the addition of 1 ml of
sodium metabisulfite (0.1%). This was followed by extensive washing
125of the gel slices with 10% methanol to remove noncovalent I as much
as possible. The gel slices were once again dried as before in
preparation for enzyme digestion (see below). Proteins contained in
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the gel slices could be labeled by this procedure to a specific 
activity of about 5 x 10^ cpm/pg of protein.
High Resolution Sodium Dodecyl Sulfate Polyacrylamide Gel 
Electrophoresis and Analysis of Gels
The procedure used for sample preparation, sodium dodecyl sulfate 
(SDS)-polyacrylamide gel electrophoresis (PAGE) on slab or 
cylindrical gels and analyses of gels by staining, fluorography or 
fractionation have been described (Montelaro and Bolognesi, 1978; 
Shealy and Reuckert, 1978; Shealy et al., 1980).
Gels used were 10% polyacrylamide and contained 0.1% SDS, 0.1%
N,N,N',N'-tetramethylenediamine, 0.5 M or 1.0 M urea and 0.1 M sodium 
phosphate, pH 7.2. Slab gel dimensions were 14 cm x 28 cm x 1.5 mm. 
The cylindrical gels were 0.6 cm in diameter by 20 to 25 cm in length. 
The electrophoresis buffer was 0.1 M sodium phosphate, pH 7.2 and 
contained 0.1% SDS and 10 mM 3-mercaptopropionate.
Aqueous samples in 10 mM phosphate buffer pH 7.2, containing 
unlabeled or radioactive proteins, were made 1% in SDS and
2-mercaptoethanol each in a total volume of 100-200 pi and were heated 
in a boiling water bath for 3 min. Sucrose was added to a final 
concentration of 20 to 30%, and 1 pi of 0.5% bromophenol blue in
0.02 N sodium hydroxide was added to each sample. Samples were 
layered onto the prerun gels and were electrophoresed at 50 mA per 
slab gel and at 8 mA per tube gel for about 18-20 h. Changes in pH 
were prevented by circulating the buffer between upper and lower 
buffer chambers during electrophoresis.
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For non-reducing SDS-PAGE analysis, 2-mercaptoethanol was omitted 
from the sample preparation, and 3-mercaptopropionate was excluded 
from running buffer.
When samples contained non-radioactive proteins, gels were 
stained with 0.25% Coomassie Brilliant Blue dye in acetic acid: 
methanol: water (92:454:454, v:v:vD) for 1 h and destained extensively 
with 7.5% (v/v) acetic acid and 25% (v/v) methanol in water to reveal 
the protein bands.
For analysis of radioactive samples on tube gels, an opaque 
"crushing plug" of highly cross-linked polyacrylamide (40%) was 
polymerized on top of the experimental gel after electrophoresis, and 
the gels were crushed bottom first into scintillation vials with a 
Gilson automatic fractionator (Gilson et al., 1972). After overnight 
elution of radioactive fractions into water, 2 ml of tritosol was 
added to each fraction, mixed with and counted in a scintillation 
counter.
Radioactive samples analyzed on slab gels were revealed by
autoradiography or fluorography of the dried gel depending on the
3 14isotope used. Fluorography was performed for [ H] or [ C] after 
treatment of the slab gel with autofluor (National Diagnostics) for
1-2 h. (Shealy et al., 1980).
Discontinuous SDS-PAGE
For some experiments, e.g. peptide analysis after limited 
proteolysis by the method of Cleveland et al., (1977), the 
discontinuous gel system described by Laemmli (1970) was used. A 15% 
acrylamide slab gel (acrylamide: biscrylamide:: 40:1) containing 10% 
SDS, 0.08% TEMED and 1% ammonium persulfate was prepared in 0.375 M
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Tris-HCl buffer, pH 8.8. A 4% stacking gel (3 to 4 cm in height) was 
overlayered on the 15% separating gel.
Samples (50-100 pi) were prepared in a disruption buffer 
consisting of 0.0625 M Tris-HCl buffer, 0.2% SDS, 5%
2-mercaptoethanol, 6 M urea and 10% glycerol, adjusted to pH 6.8 and 
heated 100°C for 3 min. The electrophoresis buffer was 10 mM 
Tris-glycine with 0.1 SDS, pH 8.4. Runs were carried out at 35 mA for 
15-18 h.
Guanidine Hydrochloride Gel Filtration
The procedures used for sample preparation and the conditions 
used for guanidine hydrochloride (GHC1) gel filtration (GF) were based 
on the methods of Green and Bolognesi (1974) and Montelaro et al. 
(1978, 1982). Routine procedures for solubilizing retrovirus protein 
samples in guanidine hydrochloride incompletely dissociate the 
proteins of EIAV, some of which then chromatograph together in the 
void volume as aggregates. However, it was found that EIAV proteins 
can be resolved more efficiently if the virion lipids are extracted 
with acetone before the proteins are treated with guanidine 
hydrochloride (Montelaro et al., 1982). Thus, in a typical 
preparative experiment about 30 mg of purified EIAV in 4 ml of 10 mM 
sodium phosphate buffer, pH 7.2 was mixed with 10 volumes of cold 
acetone and incubated at 0-4°C for 45 min with frequent mixing. The 
resulting protein precipitate was collected by centrifugation in a 
Sorvall SS34 rotor at 10,000 rpm (10,000 x g) for 30 min, and the 
supernatant acetone phase containing viral lipid was removed. The 
protein pellet was then solubilized in 4 ml of 8 M guanidine 
hydrochloride in 50 mM Tris buffer, pH 8.5, containing 2%
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2-mercaptoethanol by heating in a boiling waterbath for 5 min and at 
45°C for 45 min. Any insoluble material was removed by another 
centrifugation, but usually quantitative solubilization of the 
starting virus protein was achieved. Dextran blue and DNP-alanine 
were added to the final concentrations of 0.08% and 0.025%, 
respectively.
The solubilized proteins were then analyzed on a column 
(1.5 x 95 cm) of Sepharose 6B eluted with 6 M guanidine hydrochloride 
in 20 mM sodium phosphate buffer, pH 6.5, at a flow rate of 1.2 to 
1.6 ml/h. The recommended sodium acetate buffer, pH 5.0 (Green and 
Bolognesi, 1974), was not used as an eluting buffer, because it 
resulted in the rapid degradation of Sepharose matrix. The absorbance 
of the eluant was monitored at 280 nm by a continuous flow monitor, 
while fractions of about 0.5 ml were collected. The appropriate 
fractions were pooled, dialyzed for 48 h against several changes of 
100 mM ammonium bicarbonate, and finally dialyzed against 50 mM 
bicarbonate for 24 h. The dialyzed samples were lyophilized to 
dryness and suspended in an appropriate buffer. A recovery of 60 to 
70% of the initial virus protein was usually observed at this stage of 
the purification.
The radioactive virion proteins were isolated in similar manner
6 3from radiolabeled virus. Typically, 3 x 10 cpm of [ H]-leucine or 
14[ C]-leucine-EIAV was used for a preparative run. Aliquots from the 
collected fractions were counted for radioactivity, after adding 2 ml 
of tritosol. Radiolabeled protein fractions were pooled, dialysed and 
lyophilized as described above.
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Polypeptide Nomenclature and Quantitation
Two procedures, GHC1-GF and SDS-PAGE, have been particularly 
effective in elucidating retrovirus polypeptide composition and have 
therefore been chosen as a basis for deriving a nomenclature for 
virion polypeptides (August et al., 1974). Thus, a glycoprotein was 
designated by gp, and nonglycosylated polypeptide by p and a 
phosphorylated polypeptide by pp. This was followed by a number which 
indicated the apparent molecular weight of polypeptide in thousand 
daltons as estimated by one of the two techniques mentioned above.
For polypeptides of molecular weight below 30,000 daltons, estimation 
was based on the results of GHC1-GF. For polypeptides of molecular 
weight above 30,000 daltons, estimation by SDS-PAGE was chosen for 
nomenclature purposes.
Individual virion polypeptides were quantitated from SDS-PAGE
3analysis of [ H]-leucine-EIAV. Percentages of total radioactivity 
were calculated for each of the major and minor virion polypeptides by 
summing the radioactivity in each protein peak. Three SDS-PAGE and 
three GHC1-GF runs were used to average data. Total radioactivity was 
the sum total of all the counts observed in the polypeptide peaks.
From the knowledge of apparent molecular weight for each of these 
polypeptides, the numbers of polypeptide chains per virion were
g
calculated assuming a virion protein mass of 4 x 10 daltons as 
described by Davis and Rueckert (1972).
Calculations were made in two ways. First, the assumption was 
made that leucine is present in virion polypeptides in equivalent 
amounts. A second set of calculations resulted from the knowledge of
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the number of leucine residues present in each of the major internal 
polypeptides of EIAV (Montelaro et al., 1982).
Polypeptide Characterization
a. Isoelectric focussing
Protein isoelectric points were determined by using cylindrical 
polyacrylamide gels (0.6 x 10 cm) containing 7.5% acrylamide, 0.2% 
bisacrylamide, 5 M urea, and 1.6% ampholine (pH range 3.5 to 10, LKB 
Munich, Germany). Protein samples were dissolved in deionized water 
containing 5 M urea and 10% sucrose. Electrolyte solutions consisted 
of 1% ethylenediamine at the anode and 1.4% phosphoric acid at the 
cathode. Electrophoresis was carried out at 4°C at constant power (3 
watts) until less than 1 mA of current was observed (usually 10-12 h). 
Gels were then fractionated into 1 mm fractions with an automatic gel 
fractionator (Gilson Medical Electronics, Middleton, WI) (Gilson et 
al., 1972), and the fractions were assayed for pH and radioactivity 
(Montelaro et al., 1978, 1982).
b. Phosphoprotein analysis
32Purified P-EIAV was analyzed by standard high resolution
32SDS-PAGE and GHC1-GF procedures. Since viral RNA incorporates P,
32such analyses of P-EIAV were made before and after treatment with
RNase to identify the phosporylated polypeptide(s) without ambiguity.
32For RNase treatment P-EIAV was disrupted in 20 mM Tris-HCl 
buffer, pH 7.4, containing 0.1% Nonidet P-40 at 0°C for 1 h and then 
treated with RNase (0.5 mg/ml final concentrations) at 37°C for 2 h.
c. One-dimensional peptide mapping
The method used to generate peptides by limited proteolysis in 
SDS and their analysis by SDS-PAGE was essentially that of Cleveland
3et al., (1977). Purified, homogeneous preparations of [ H]-leucine 
labeled internal proteins of EIAV (p26, ppl5, pll, and p9) were taken 
in sample buffer which contained 0.125 M Tris-HCl at pH 6.8, 0.5% SDS, 
10% glycerol and 0.0001% bromophenol blue. The samples were heated to 
100°C for 2 min. Proteolytic digestions were carried out at 37°C for 
30 min by addition of given protease (chymotrypsin or aureus V8 
protease) at the final concentration of 1 Ug/10 yl. Proteolysis was 
stopped by boiling the samples for 2 min after addition of
2-mercaptoethanol and SDS to final concentrations of 10% and 2%, 
respectively.
The resultant peptides were then analyzed by electrophoresis in 
gels containing SDS in a slab gel apparatus (Studier, 1973) utilizing 
the discontinuous system described earlier (Laemmli, 1970). After the
3run, [ H]-leucine labeled peptides were detected by fluorography of 
the dried gel.
Proteases used in this experiment were quite specific in their 
action. Chymotrypsin specifically cleaves peptide bonds involving a 
carbonyl group from an aromatic amino acid (e.g. Tyr, Trp and Phe).
On the other hand, V8 protease from Staphylococcus aureus cleaves 
bonds with carbonyl group from glutamic acids, and sometimes from 
aspartic acid.
d. Two-dimensional peptide mapping
Procedures for two-dimensional peptide mapping have been 
described by Elder et al., (1977a,b). Radioiodinations of individual 
polypeptides in gel slices, after separation by SDS-PAGE, were carried 
out as described earlier. Subsequently, gel slices were dried under a 
heat lamp and vacuum. DPCC-treated trypsin (30 ug = 210 units) was
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then soaked into the gel, and 0.5 ml of 0.05 M ammonimum bicarbonate
(pH 8.0) was added. Digestion was allowed to proceed at 37°C for
20-24 h, when most of the digested peptides eluted out of the gel.
The solution containing the tryptic peptides was lyophilized to
dryness and the residue was dissolved in 20 to 50 yl of
electrophoresis solvent (acetic acid: formic acid: water:: 15:5:80).
Peptides were separated on cellulose coated thin layer plates, first,
by electrophoresis at 1000 volts. The movement of the peptides was
monitored by 1 yl of dye mixture (27, Orange G and 1% acid fuschin)
spotted at the diagonal corner. After the run, the plate was
completely dried, and separation in perpendicular direction was
accomplished by chromatography using freshly prepared n-butanol:
125pyridine: acetic acid: water (6.5:5:1:4). I-labeled peptides were 
then revealed by standard autoradiographic techniques.
Polypeptide Localization Experiments
a. Bromelain digestion
Virion surface and internal proteins were differentiated based on 
their susceptibilities to protease digestion when intact
3[ H]-leucine-EIAV was treated with bromelain. Bromelain (pineapple) 
was prepared for use by making a suspension of 150 mg of bromelain 
powder in 1.5 ml of 20 mM sodium phosphate buffer, pH 7.2, with 0.15 M 
NaCl containing 0.5 mM p-chloromecuriphenysulfonic acid. This 
reversible inhibitor was included to prevent autodigestion of 
bromelain during storage. The suspension was clarified by 
centrifugation for 20 min at 4000 rpm (1500 x g) in a Sorvall SS34 
rotor. The large, pale yellow pellet was discarded. The clear 
supernatant containing crude bromelain was diluted to 4 mg/ml with the
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same buffer, stored at -80°C, and used as the stock solution for 
subsequent experiments.
Bromelain digestion of EIAV was carried out by a modification of 
the procedure of Rifkin and Compans (1971), which was used for the 
structural analysis of spleen necrosis virus (SNV) by Mosser et al. 
(1975). In a typical experiment, 100 pi of [^H]-leucine-EIAV 
(300,000 cpm) was treated with 100 pi (=15 units) of bromelain stock 
solution and 200 pi of 0.2 M Tris-HCl buffer (pH 7.2) containing 1 mM 
EDTA and 20 mM 2-mercaptoethanol. The digestion mixture was incubated 
for 2.5 to 3 h and was then diluted to 1 ml with 10 mM Tris-HCl, 
pH 8.1, containing 1 mM EDTA, 0.3 M NaCl and 0.1% BSA and subsequently 
chilled. The chilled mixture was layered onto a 3.2 ml 10 to 20%
(w/v) sucrose gradient underlayered with a 1.0 ml 50% (w/v) sucrose 
cushion. Sucrose solutions were in the same buffer that was used to 
dilute the digestion mixture. The gradients were centrifuged for 1 h 
at 30,000 rpm (100,000 x g) and 4°C in a Beckman SW50.1 rotor. 
Fractions were collected through a needle puncturing the bottom of the 
tube, and the virus peak was located by determining the radioactivity 
of samples of each fraction. Peak fractions were pooled, diluted with 
10 mM Tris-HCl, pH 8.1, 1 mM EDTA, 0.3 M NaCl and 0.1% BSA, and the 
virus was pelleted by centrifugation at 45,000 rpm (240,000 x g) for 
45 min in SW50.1 rotor. Pelleted virus was then analysed by SDS-PAGE.
b. Virion surface radioiodination using lactoperoxidase.
Virion surface and internal proteins were also differentiated 
based on their susceptibilities to surface radioiodination using 
lactoperoxidase. The method for radioiodination has been described in 
an earlier section.
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c. Production of a subviral particle (ribonucleoprotein).
A subviral particle (ribonucleoprotein, RNP) of an apparent
density 1.31 g/cm3 was prepared by treatment of virus with Nonidet
P-40 (NP-40, a nonionic detergent) and dithiothreitol (DTT) as
reported by Davis and Rueckert (1972) and Mosser et al. (1975) with
some modifications. A 4 ml continuous gradient was prepared from 30%
sucrose in 10 mM Tris-1 mM EDTA, pH 8.1, with 0.4% dithiothreitol and
65% sucrose in the same buffer, made with D2O. About 5 mg of EIAV was
treated with 1 ml of 0.5% NP-40 and 1% DTT in 10 mM Tris-1 mM EDTA
buffer, pH 8.1, at 4°C and layered immediately onto the above chilled
sucrose gradient and centrifuged at 45,000 rpm (240,000 x g) and 4°C
for 3 h in Beckman SW50.1 rotor. Fractions were collected by
puncturing the tube at the bottom with a needle. In a parallel
3analytical run made with [ H]-leucine-EIAV, fractions were assayed for 
radioactivity and protein peaks corresponding to disrupted viral 
proteins and subviral particle were detected. This helped to locate 
the appropriate fractions from the gradient containing the 
nonradioactive EIAV. Protein peaks were pooled and treated with cold 
10% TCA to precipitate the proteins. The precipitated proteins were 
pelleted by centrifugation at 10,000 rpm (10,000 x g) for 20 min in 
SS34 rotor. Pellets were washed with chilled acetone and finally 
dried under nitrogen. Pellets were suspended in 10 mM phosphate 
buffer, pH 7.2, to be analyzed by SDS-PAGE as described earlier.
Glycoprotein Purification and Analysis
a. Lentil lectin affinity chromatography.
Procedures for lectin affinity chromatography of EIAV have been 
described and evaluated previously (Monetlaro, et al., 1983).
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Typically, about 2 mg of EIAV was treated with ten volumes of cold 
acetone to remove viral lipids and to preciptate viral proteins, which 
were collected by centrifugation at 10,000 rpm (10,000 x g) for 10 min 
at 4°C in Sorvall SS34 rotor. The dried protein pellet was 
solubilized in buffer A (20 mM Tris-HCl, 100 mM NaCl, pH 8.3) 
containing 0.5% 7-deoxycholate (sodium salt) (DOC) and incubated at 
37°C for 30 min with intermittant vortexing and brief episodes of 
sonication. It was then centrifuged at 10,000 rpm for 10 min in SS 34 
rotor to remove insoluble material. Solubilized proteins were loaded 
on a Lens culinaris (lentil) lectin Sepharose column (1-2 ml bed 
volume), preequilibrated with buffer A containing 0.1% DOC.
Nonbinding proteins were eluted when washed with the same buffer. The 
column was then washed with buffer A-0.1% DOC containing 0.2 M 
a-methylglucoside to remove bound glycoproteins. Nonbinding and 
binding proteins were detected by monitoring the column effluent at 
280 nm. Appropriate fractions were pooled, dialyzed against 100 mM 
NH^HCOg and lyophilized. The protein residues were then dissolved in 
10 mM phosphate buffer, pH 7.2 and were separated by SDS-PAGE on 7.5% 
acrylamide slab gels as described earlier,
b. Glycoprotein Variation Study
Isolated glycoproteins from prototype virus and other EIAV 
isolates were suitable for radioiodination and for further analysis by 
two dimensional peptide mapping procedures of Elder et al., (1977a,b), 
which enabled us to detect the minor differences between the two or 
more proteins. Details of these procedures have been described in 
earlier sections.
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In order to assay for variation in the glycosylated regions of
the virion glycoproteins the following strategies were used. First,
3[ H]-glucosamine labeled glycoprotein (gp90) was isolated and purified
3by a preparative SDS-PAGE of [ H]-glucosamine-EIAV. The purified 
3[ H]-glucosamine-gp90 was then incubated with DPCC-trypsin, and the 
resultant peptides were separated on cellulose coated thin layer 
plates by two-dimensional peptide mapping procedure, as described 
before.
125Secondly, I-labeled peptides of gp90, prepared as described 
earlier, were separated into glycosylated (binding) and 
nonglycosylated (non-binding) components by lentil lectin affinity 
chromatography. The separated peptide pools were dialyzed against 
100 mM NH^HCO^ using Spectrapor 3 dialysis tubing, which was boiled in 
10 mM EDTA, pH 8.0 to reduce the exclusion limit to 700 daltons (Dr. 
Blackeney, personal communication). The peptides were then 




I. ANALYSES OF POLYPEPTIDES OF EIAV
14The polypeptides of EIAV were analyzed using [ C]-leucine or 
[^H]-leucine labeled EIAV, [^H]-glucosamine labeled EIAV and 
unlabeled EIAV, prepared and purified as described in Chapter II. 
Previous experience with retroviruses has consistently emphasized the 
need to utilize several analytical techniques in identifying virion 
structural polypeptides (Montelaro et al., 1978). In this study, EIAV 
polypeptides were analyzed by the complementary techniques of high 
resolution sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE), and guanidine hydrochloride gel filtration (GHC1-GF) on a 
column of Sepharose 6B (Parekh et al., 1980; Montelaro et al., 1982), 
as described earlier.
SDS-PAGE ANALYSIS
Radioactive EIAV was analyzed on tube gels which were
fractionated after the run to determine the position of radioactivity.
A representative electrophoretic radioactivity profile of purified 
14[ C]-leucine labeled EIAV is presented in Figure III-1A.
3t H]-leucine labeled Friend murine leukemia virus (FLV), a prototype-C 
oncornavirus, was analyzed simultaneously for comparative purposes and 
as a molecular weight calibration standard. FLV proteins are denoted 
in italics (gp71, p30, pl5E, pl5C, pl2, pl2E and plO), while EIAV 
proteins are labeled in block letters (gp90, p70, p61, gp45,
52
Figure III-l: SDS-PAGE analysis of radioactively labeled EIAV (A)
[^C]-leucine EIAV (----) vs. [^H]-leucine FLV (--- ) (B)
3[ H]-glucosamine EIAV.
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p30, p26, p23, ppl5, pll and p9), designated according to the 
nomenclature system proposed by August et al. (1974) (see below).
SDS-PAGE analysis of EIAV reveals four major low-molecular weight 
polypeptides, p26, ppl5, pll and p9, and also resolves reproducibly 
several high-molecular weight components. These include two 
polypeptides of 90,000 (gp90) and 45,000 (gp45) daltons molecular 
weight, which are glycosylated (see below) and four minor 
non-glycosylated proteins designated as p70, p61, p30 and p23.
3[ H]-leucine labeled FLV, simultaneously resolved on the same tube 
gel, gave an analogous radioactivity profile (broken line) with four 
major low molecular weight proteins, p30, pl5, pl2 and plO; and a few 
high-molecular weight components, including a glycosylated protein, 
gp71 (Montelaro and Bolognesi, 1978).
To identify which of the above EIAV polypeptides were 
3glycosylated, [ H]-glucosamine labeled EIAV was propagated in fetal 
equine kidney cells, purified and analyzed by SDS-PAGE in tube gels 
(Figure III-1B) as described above for radioactive leucine labeled
3EIAV. The radioactivity profile of [ H]-glucosamine-EIAV shows two 
distinct peaks which coincided with polypeptides of apparent molecular 
weight 90,000 and 45,000 daltons. These proteins, being glycosylated, 
were designated as gp90 and gp45.
Frequently, EIAV pll migrates as a shoulder to ppl5, and they do 
not separate on SDS-PAGE. A similar problem has been encountered 
during the polypeptide analysis of spleen neicosis virus (Mosser et 
al., 1975), especially in gels of leucine labeled virus. Use of 1 M 




Purified radioactive virus was analyzed by GHC1-GF as described
for FLV by Montelaro et al. (1978). The chromatographic radioactivity 
14profile of [ C]-leucine labeled EIAV (solid line) is presented in
3Figure III-2A with a simultaneous analysis of [ H]-leucine FLV used 
for comparison and as a molecular weight calibration standard (broken 
line). FLV proteins are indicated in italics (gp71, p30, pl5, pl2 and 
plO) and EIAV proteins are labeled in block letters (gp90, p26, ppl5, 
pll and p9). The void volume is represented by a radioactive peak, 
designated Vo, while DNP-alanine serves as the dye marker for the 
total column volume.
The chromatographic analysis of the radioactive EIAV reveals six 
distinct peaks of radioactivity. As observed with other 
oncornaviruses, the first protein(s) to elute from GHC1-GF are 
contained in the void volume fractions of the column indicating an 
apparent molecular weight of at least 100,000 daltons. The next EIAV 
protein(s) elutes as a relatively broad peak with an apparent 
moleuclar weight of about 74,000. This component is followed by the 
major EIAV structural polypeptide (p26) which displays a molecular 
weight of 26,000 and, in succession, by three additional components of 
15,000 (ppl5); 11,000 (pll) and 9000 (p9) molecular weights, 
respectively.
A comparison of the respective polypeptide profiles of FLV and 
EIAV, shown in Figure III-2A, indicates that the two viruses contain 
remarkably similar structural components. However, two differences 
are noted reproducibly, i) the percentage of radioactivity eluting in 
the void volume is higher in the case of EIAV than in the case of FLV
Figure III-2: GHC1-GF analysis of radioactively labeled EIAV (A)
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and ii) EIAV and FLV polypeptides display somewhat different apparent 
molecular weights.
3In an analogous experiment, purified [ H]-glucosamine EIAV was
analyzed by GHC1-GF (Figure III-2B) to identify the glycoproteins in
relation to [^C]-leucine proteins of EIAV (Figure III-2A) . The
conditions of analysis were identical. The chromatographic
3radioactivity profile of [ H]-glucosamine-EIAV gave only two distinct 
radioactivity peaks, one of which eluted at the void volume fractions, 
representing apparent molecular weight in excess of 100,000 daltons. 
The second peak eluted with an apparent molecular weight of 74,000. 
Proteins contained in these radioactivity peaks were identified from 
their subsequent SDS-PAGE analysis (see below), which indicated that 
all of gp45 eluted in the void volume fractions along with part of 
gp90, and the remaining gp90 was present in the second peak of 
radioactivity.
SDS-PAGE Analysis of GHC1-GF Pools
It is well established that certain oncornavirus proteins (eg.
RSV pl5 and pl2) display different apparent molecular weights when 
analyzed by SDS-PAGE and GHC1-GF (August et al., 1974). Thus, to 
establish a definitive correlation between the EIAV proteins resolved 
by these two analytical systems, each radioactive component separated 
by GHC1-GF of [^H]-leucine EIAV (cf. Figure III-2A) was isolated and 
subjected to high resolution SDS-PAGE. The results of this experiment 
are presented in Figure 3 and can be compared to the electrophoretic 
profile of purified EIAV shown in Figure 1A. The data in Figure III-3 
demonstrate that the GHC1-GF components designated as EIAV p26, ppl5, 
pll and p9 (Figure III-2A) contain a single homogeneous peak of
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Figure III-3: SDS-PAGE analysis of the individual protein fractions
obtained by GHC1-GF of [ H]-leucine EIAV as described in Figure 
III-2A. A-F correspond to the six radioactive components in the 
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radioactivity upon analysis by SDS-PAGE (Figure III-3C-F, 
respectively). In contrast, the void volume fractions from GHC1-GF 
reveal a complex profile in SDS-PAGE (Figure III-3A) including the 
major proteins designated gp90, gp45, p26 and ppl5 as well as certain 
high molecular weight minor polypeptides. The presence of substantial 
quantities of p26 and ppl5 in the void volume fractions is surprising 
and suggests that even treatment of the virus with 8 M GHC1 at 100°C 
fails to completely disrupt the intermolecular interactions between 
some of the EIAV polypeptides. The presence of gp90 in the void 
volume may be explained by the fact that gp90 elutes immediately after 
the void volume fractions of the column (Figure III-3B), along with 
several of the minor high molecular weight virion components. On the 
other hand, gp45 elutes exclusively in the void volume fractions, 
apparently in an aggregated state, analogous to murine pl5E/pl2E and 
avian gp35 (Montelaro et al., 1978).
The chromatographic elution pattern of the EIAV glycoproteins, 
gp90 and gp45, was further confirmed when the two radioactivity peaks
3obtained on GHC1-GF analysis of [ H]-glucosamine-EIAV (Figure III-2B) 
were isolated and subjected to high resolution SDS-PAGE. The results 
of this experiment are presented in Figure 4 and can be compared to
3the electrophoretic profile of purified [ H]-glucosamine-EIAV shown in 
Figure III-1B. Void volume fractions from the GHC1-GF analysis 
(Figure III-2B) reveal some of the virion gp90 and all of the virion 
gp45 upon analysis by SDS-PAGE (Figure II1-4A). In contrast, the 
second glycosylated chromatographic peak to elute from the GHC1 column 
contains only gp90 as demonstrated by SDS-PAGE (Figure III-4B). Thus,
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Figure III-4: SDS-PAGE analysis of the individual protein fractions
3obtained by GHC1-GF of [ H]-glucosamine EIAV as described in 
Figure III-2B. A and B correspond to the two radioactive 
components resolved by gel filtration in the order of their 


























all of gp45 preferentially elutes in the void volume, apparently in an 
aggregated form, reflecting its hydrophobic property.
Preparative GHC1-GF runs were made, in an analogous manner, to 
purify the major nonglycosylated polypeptides of EIAV. These 
preparative runs demonstrated that if the EIAV proteins are 
precipitated and lipids removed by ten volumes of cold acetone prior 
to GHCI-GF analysis, the problem of aggregation of EIAV proteins can 
be avoided with only negligible amounts of proteins eluting in the 
void volume (Montelaro et al., 1982).
Also, the chromatographic analysis of unlabeled EIAV, monitoring 
absorbance at 280 nm, gave a profile different form the one obtained 
using leucine labeled EIAV, apparently due to differences in 
absorbance by each polypeptide. EIAV pll did not show any absorbance 
at 280 nm, and this correlated with the absence of tyrosine and 
tryptophan in this protein (Montelaro et al., 1982).
Relative Abundance of Polypeptides
A set of calculations for the major and minor polypeptides of 
EIAV, analyzed by SDS-PAGE and GHCI-GF, is presented in Table III-l. 
The first column shows the designation of each of these polypeptides, 
the nomenclature being based on recommendation of August et al.
(1974). Second column represents the average percentage of total 
radioactivity found in each of these components. This is followed by 
apparent molecular weights calculated using FLV polypeptides as 
molecular weight standards. Molecular weight estimations by two 
procedures differ for some of this polypeptides, but only one of the 
two values is selected for nomenclature (August et al., 1974; Parekh 
et al., 1980).
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gp90 6.0 74,000 90,000 300 -
gp45 3.0 > 100,000 45,000 300 -
p26 45.0 26,000 26,000 6,900 7,700
PPl5 28.5 15,000 15,000 7,600 5,800
pll 5.5 11,000 12,000 2,000 2,600
p9 7.5 9,000 10,000 3,300 3,200
Minor
p70 1.0 - 70,000 60 -
p61 1.0 - 61,000 70 -
p30 1.5 - 30,000 200 -
P23 1.0 - 23,000 170 -
g Protein nomenclature based on recommendations of August et al., 
(1974).
k Calculated from the data presented in Figure III-l and III-2, 
averaging percentage cpm from GHCI-GF and SDS-PAGE.
C Calculated by GHCI-GF and SDS-PAGE using FLV proteins as a molecular 
weight standards.
d 8Calculated assuming that virion protein mass is 4 x 10 daltons as
described by Davis and Rueckert (1972). Column A = Supposition is
made here that % leucine distribution in virion polypeptides is same.
Column B = Calculated with the knowledge of actual % of leucine
present in the major nonglycosylated polypeptides (Montelaro et al.,
1982).
Retroviruses are estimated to have a protein mass of 4 x 10 
daltons (Davis and Rueckert, 1972). Taking this value for the protein
3mass of EIAV and assuming that leucine, and hence [ H]-leucine, is 
evenly distributed among polypeptides, an estimate of the number of 
copies of each polypeptide constituting the virion particle can be 
calculated (Table III-l). Both glycoproteins, gp90 and gp45, are 
found in 300 copies each per virion, while the major nonglycosylated 
proteins are present from 2000 copies to 7600 copies per virion.
Other minor polypeptides ranged from below 100 to 200 copies per 
virion.
From the knowledge of the number of leucine residues present per 
molecule (Montelaro et al., 1982), the corrected number of major 
nonglycosylated polypeptide chains per virion can be calculated.
These are presented in the last column. The observed differences in 
stoichiometry probably reflect the inaccuracy of the assumption of an 
equal distribution of leucine residues in each EIAV protein.
II. CHARACTERIZATION OF EIAV POLYPEPTIDES
Peptide Mapping
a). Cleveland's Limited Proteolysis (One-dimensional peptide 
mapping).
Previous reports from other laboratories (Cheevers et al., 1978, 
Crawford et al., 1978; Ishizaki et al., 1978) have described fewer 
than the four major nonglycosylated EIAV proteins reported by us.
Thus we sought to establish conclusively whether the four virion 
proteins (p26, ppl5, pll and p9) resolved by analytical procedures 
used here are unique or share amino acid sequences, perhaps as a 
cleavage product of each other. Homogeneous preparations of
3[ H]-leucine labeled p26, ppl5, pll and p9 were isolated by a
3preparative GHCI-GF of [ H]-leucine EIAV. Purified proteins were 
then subjected to limited proteolysis by chymotrypsin or Ŝ. aureus 
protease V8, and the resulting peptides were analyzed by SDS-PAGE, as 
described by Cleveland et al. (1977). The autoradiograph in Figure 
III-5 shows that the fragments produced by protease V8 treatment of 
p26, ppl5 and pll are unique. A large amount of substrate protein in 
each case remains undigested, even after 2 h of incubation. In 
contrast, p9 appeared to be digested rapidly to small fragments within 
the normal 30 min digestion period, and the resulting fragments 
apparently migrated from the gel. In a complementary digestion, 
carried out with chymotrypsin, SDS-PAGE analysis revealed novel 
chymotryptic peptides generated from p26, ppl5 and p9; pll was 
apparently cleaved to small fragments which migrated from the gel.
The unique peptides generated by the two proteases and the 
characteristic efficiencies of cleavage under identical conditions 
indicate that EIAV p26, ppl5, pll and p9 contain unique amino acid 
sequences and therefore are not related.
b). Two-Dimensional Peptide Mapping Procedure.
In the course of further investigation, the two-dimensional 
peptide mapping procedure of Elder et al. (1977a) was developed and 
used to compare EIAV proteins. This method is more sensitive and can 
easily detect different amino acid sequences between two or more 
proteins. EIAV nonglycosylated proteins were separated on SDS-PAGE by 
electrophoretic analysis of about 100 ug of EIAV proteins on a slab 
polyacrylamide gel. Glycosylated proteins, gp90 and gp45, were 
obtained after a lectin affinity chromatography separation, followed
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Figure III-5: SDS-PAGE analysis of peptide fragments generated by
3limited proteolysis of [ H]-leucine labeled EIAV p26, ppl5, pll, 
and p9, using either S_. aureus protease V8 or chymotrypsin. 
Untreated radioactive proteins are included for reference.
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by SDS-PAGE analysis of lectin binding fraction (see below). The EIAV 
proteins, thus separated into individual components by SDS-PAGE, were 
detected by Coomasie blue staining and excised from the gel. The 
coomasie blue stained gel band of each protein was radioiodinated and 
digested with trypsin in situ as described (Elder et al., 1977b). 
Radioiodinated tryptic peptides of each protein were then separated on 
cellulose coated thin layer plates using electrophoresis in one 
dimension and chromatography in the second dimension as described in 
Chapter II. Autoradiographs of such maps are presented in Figure 
III-6.
The peptide maps of p26, ppl5 and p9 are unique and 
characteristic of individual polypeptides (Figure III-6). The p26 map 
revealed about 12 major peptides distributed in a characteristic 
pattern. The ppl5 map also demonstrated about 12 major spots, but 
their distribution was distinct from that of p26. The p9 digest 
showed only four to five iodinated fragments. None of these maps 
showed common peptides as determined by their position on 
two-dimensional maps. The pll could not be radioiodinated by the 
chloramine-T method used, due to lack of tyrosine residues (see below; 
Montelaro et al., 1982), and hence could not be mapped by this 
procedure. Thus, the results of this more sensitive procedure 
confirmed the uniqueness of these polypeptides. Their uniqueness was 
further reflected in serological differences and absence of 
immunological cross-reactivity as determined by enzyme-linked 
immunosorbent assays (Montelaro et al., 1982).
Peptide maps of virion glycoproteins, gp90 and gp45, are also 
presented in Figure III-6. Both of these maps are complex with more
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125Figure III-6: Two-dimensional peptide analysis of I-labeled EIAV
major proteins digested with DPCC-treated trypsin. E = 
electrophoresis, C = chromatography.
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125than 30 I-labeled peptides. Such complexities may result in part 
from inherent heterogeneity in these glycoproteins (Strand and August, 
1977; Schultz and Oroszlan, 1979). Also a peptide with mono and 
di-iodinated tyrosine residues may migrate differently, thus 
contributing further to the complexity of the map. Regardless of the 
map complexity, they are reproducible and characteristic of a 
particular glycoprotein. Maps of gp90 and gp45 clearly demonstrate 
that these peptide fingerprints are distinct, and thus gp90 and gp45 
are not related or do not have common amino acid sequences. This is 
in contrast to murine viruses, where gp45 has been shown to be a 
degradation product of the major surface glycoprotein by peptide 
mapping analysis (Elder et al., 1977a).
When analyzed on SDS-PAGE containing 7.5% acrylamide, gp45 could 
be resolved into two bands. Separate peptide mapping analysis of two 
resolvable bands of gp45 gave identical maps (data not shown).
Isoelectric Focussing: pi Determination
The isoelectric point of each major nonglycosylated polypeptide
3was determined by subjecting purified [ H]-leucine labelled 
preparations of p26, ppl5, pll and p9 to isoelectric focussing on 
cylinderical polyacrylamide gels, as described earlier. Each protein 
preparation displays a single homogeneous peak of radioactivity upon 
analysis by SDS-PAGE (Figure III-3C-F, Parekh et al., 1980).
The radioactivity profiles of isoelectric focussing gels in Figure 
III-7 show single homogeneous peaks of radioactivity for EIAV p26 
(Figure III-7A) with a pi of 6.2, and for EIAV p9 (Figure III-7C) with 
a pi of 5.0. In contrast to the single isoelectric species described 
above, EIAV ppl5 reproducibly focussed in a characteristic
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3Figure III-7: Isoelectric focussing of [ H]-leucine labeled EIAV
proteins on cylinderical polyacrylamide gels.
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heterogeneous pattern, with major portions of the protein appearing at 
pi values of 5.7, 6.6, 7.6 and 8.3 (Figure III-7B). This 
heterogeneous pattern varied only slightly when ppl5 was isolated from 
different virus preparations. The phosphoproteins of avian and 
mammalian oncornaviruses have been shown to display a similar charge 
heterogeneity, reflecting different degrees of phosphorylation (Hayman 
et al., 1977). Subsequent results from amino acid analysis after 
short term acid hydrolysis of ppl5 demonstrated that ppl5 is indeed a 
phosphoprotein (Montelaro et al., 1982).
EIAV pll could not be focused on the usual gel ranging in pH from 
2 to 10. When isoelectric focussing gels were intermittantly 
terminated before completion, a small peak of radioactivity was 
observed migrating towards the cathode, and eventually migrating from 
the gel, indicating a pi of > 10.0 (data not shown).
Phosphoprotein Analysis
One or more polypeptides of retroviruses are usually
phosphorylated (Hayman et al., 1977). The major viral phosphoprotein
has been implicated in structural and regulatory functions (Montelaro,
et al., 1978; Leis et al., 1978) by virtue of its location in the
intact virion and its specific affinity to viral RNA. Thus we sought
32to detect possible EIAV phosphoprotein(s) by propagating P-EIAV in
32fetal equine kidney cells (Pal et al., 1975). P-EIAV was purified
3and subjected to SDS-PAGE analysis along with [ H]-leucine labeled
EIAV. The resulting electrophoretic radioactivity profile is
32presented in Figure III-8A. A P peak observed at the top of the gel 
(4-5 mm) apparently represents high molecular weight viral genomic RNA
Figure III-8: Phosphoprotein analysis. (A)
(----) vs [3H]-leucine EIAV (----- ) (B)
(----) vs [3H]-leucine EIAV (----).





















which barely enters the 10% acrylamide gel. In addition, the 
32P-radioactivity profile shows three more peaks. A small peak at
about 55 mm coincides with p61 (See Figure III-lA) and another one at
32155 mm coincides with EIAV ppl5. A large, broad P-peak migrating
ahead of the dye represents virion phospholipid. The results seemed
to indicate that EIAV ppl5 and p61 are phosphorylated. However, the
results of further experiments did not support this conclusion.
32 3Samples of P-EIAV and [ H]-leucine-EIAV were simultaneously
analyzed by GHCI-GF analysis, and the radioactivity elution profile of
such an analysis is presented in Figure III-8B. The results
32demonstrate that a large amount of P label elutes in the void
32volume, representing genomic viral RNA. However, no P radioactivity
3eluted along with H-leucine labeled ppl5 or other EIAV proteins. The
32P labeled lipid eluted in the excluded volume of the column. Thus, 
32the P radioactivity peak migrating in place of ppl5 on SDS-PAGE 
apparently did not represent ppl5. That this peak is not ppl5, but 
represents probably host tRNAs carried by virions, was confirmed by
its susceptibility to RNase digestion. SDS-PAGE analysis of RNase
32 32treated P-EIAV did not show any of the P-radioactivity peaks seen
32in Figure III-8A, except the P-labeled phospholipid peak (data not
32shown). Also, when viral RNA from P-EIAV was extracted using phenol
and chloroform to remove proteins, and analyzed on SDS-PAGE,
32demonstrated RNase susceptible P-radioactivity peaks.
Results of amino acid analysis of ppl5 (Montelaro et al., 1982)
did provide evidence that ppl5 is, in fact, a phosphoprotein.
32However, we could not incorporate P in EIAV ppl5 by labeling the 
propagating virus in tissue culture by the method of Pal and
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Roy-Burman (1975). Modifications (overnight growth in phosphate-free
media or use of undialyzed fetal calf serum) of the labeling procedure
yielded the same results. The reasons for our failure to incorporate 
32P into EIAV ppl5 are not clear, but this may be due to suboptimal 
labeling conditions for the equine kidney cells.
Radioiodination of EIAV proteins in vitro
Proteins can be radioiodinated to a very high specific activity
by several procedures (Hunter and Greenwood, 1962; McFarlane, 1958;
Bolton and Hunter, 1973; Morrison et al., 1971). Of these,
radioiodination of tyrosine residues of protein using chloramine-T as
an oxidizing agent is a widely used method (Montelaro and Bolognesi, 
1251979). I-labeled proteins can be used for a variety of biochemical 
and immunological techniques (Mosser et al., 1975; Morrison et al., 
1971).
The major nonglycosylated polypeptides of EIAV were purified to 
homogeneity by GHCI-GF analysis and subsequent ion exchange 
chromatography, where required (EIAV pll and p9; Montelaro et al.,
1982).. Following iodination, TCA precipitable counts obtained for 
each of these proteins were calculated for nmol amounts and these 
iodination efficiencies are presented in Table III-2. It is evident 
that pll can not be labeled by chloramine-T radioiodination procedure. 
This result correlates with the results of amino acid analysis of pll 
(Montelaro et al., 1982), showing that pll does not contain tyrosine 
residues. Relative iodination efficiencies of p26, ppl5 and p9 
perhaps reflects the accessible tyrosine residues.
80
Table III-2. Iodination efficiencies of EIAV nonglycosylated 
polypeptides by chloramine-T method.
No. of 
tyrosine/molecule* ^^1 dpm/nmol
p26 4 1 x 107
PP15 3 2.3 x 106
pll 0 —
p9 3 6 x 107
* Montelaro et al. (1982).
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III. POLYPEPTIDE LOCALIZATION
According to the current model for oncornavirus structure, the 
location of the structural polypeptides of virions can be correlated 
with certain biochemical properties (Bolognesi et al., 1978; Montelaro 
and Bolognesi, 1978; Montelaro et al., 1978; Stephenson et al., 1977). 
EIAV is found to have a polypeptide composition analogous to that of 
oncornaviruses. This analogy included the number of major structural 
polypeptides, their molecular weight range, secondary modifications, 
eg. glycosylation and phosphorylation, of some polypeptides, and pi 
values for major non-glycosylated proteins. Thus, certain experiments 
were performed to localize the structural components of EIAV and to 
compare these localizations with those reported for prototype-C 
oncornaviruses.
1. Outer Envelope Proteins
The protease bromelain has been used routinely to distinguish 
surface proteins from proteins sequestered from enzymatic digestion by 
the virion lipid bilayer (Rifkin and Compans, 1971; Mosser et al., 
1975).
3Thus, [ H]-leucine labeled EIAV was digested with bromelain, and
the treated particle was analyzed by SDS-PAGE (Figure III-9). A
14comparative electrophoretic pattern of untreated [ C]-leucine EIAV is 
shown superimposed in the same figure (broken line) as a reference.
3The treatment of [ H]-leucine EIAV with bromelain resulted in complete 
removal of the two viral glycoproteins (gp90 and gp45), whereas the 
major nonglycosylated proteins (p26, ppl5, pll and p9) were not 
affected by enzyme digestion. Although, ppl5 and pll were not 
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3Figure III-9: SDS-PAGE analysis of bromelain treated [ H]-leucine







comigration of some glycoprotein fragments in that region of the gel
(Montelaro et al., 1978), the presence of pll, in addition to p26,
ppl5 and p9, could be demonstrated by GHCI-GF analysis of bromelain
treated virus preparations (data not shown). In addition, bromelain 
3digestion of [ H]-glucosamine labeled EIAV, in which only gp90 and
gp45 were radiolabeled (Parekh et al., 1980), resulted in the complete
loss of radioactivity from these virus particles. Thus, gp90 and gp45
appear to form the surface projections of the virus, whereas p26,
ppl5, pll and p9 constitute the internal virion components.
Additional evidence for this localization came from
surface-specific radioiodination. Lactoperoxidase catalyzed
iodination is reputed to label only polypeptides which are exposed on
the outside surface of a membrane (Marchalonis et al., 1971; Phillips
and Morrison, 1971; Rifkin and Compans, 1971; Mosser et al., 1975).^
125EIAV was labeled in vitro with I using lactoperoxidase, purified 
and subsequently analyzed by SDS-PAGE. The radioactivity profile 
(Figure 111-10) reveals five peaks of radioactivity, two of these 
coinciding with virion gp90 and gp45. Viral proteins have not been 
observed comigrating in the position of the other two peaks [between 
gp90 and gp45 (MW = 68,000) and between p26 and ppl5 (MW = 20,000). 
These proteins, therefore, were believed to be contaminating 
proteins from the tissue culture system which copurify with virions. 
The major nonglycosylated viral proteins, p26, pll and p9 were not 
significantly labeled, except ppl5, which was labeled to a small 
extent. This may indicate its location close to the envelope. Thus, 
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Figure 111-10: SDS-PAGE analysis of lactoperoxidase-radioiodinated
EIAV.
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are on the outside of the lipid envelope while nonglycosylated
polypeptides p26, ppl5, pll and p9 are internal.
The envelope proteins in certain avian and murine oncornaviruses
have been observed to be intermolecularly linked by disulfide linkages
(Montelaro et al., 1978). Thus, we sought to investigate the presence
or absence of disulfide linkages between EIAV gp90 and gp45. For 
3these purposes [ H]-glucosamine labeled EIAV was subjected to 
nonreducing SDS-PAGE analysis as described (Montelaro et al., 1978). 
Analysis of the radioactivity in the gel gave a profile identical to
3the reducing SDS-PAGE analysis of [ H]-glucosamine labeled EIAV 
(Figure III-1B), demonstrating that gp90 and gp45 are not disulfide 
linked.
2. Ribonucleoprotein (RNP) Analysis
The identity of the internal protein(s) associated with the viral 
RNA was determined by treating purified EIAV with Nonidet P-40 (NP-40) 
to release the virion ribonucleoprotein complex, which was then 
isolated by centrifugation on a sucrose-D20 gradient (Davis and 
Rueckert, 1972; Mosser et al., 1975). The experiment was carried out
3with [ H]-leucine labeled EIAV in a parallel analysis with unlabeled
3EIAV. The analysis of NP-40 treated [ H]-leucine-EIAV on sucrose-D20 
gradient is shown in Figure III-l1A. A small peak of radioactivity 
with a density of about 1.31 g/ml is observed in fractions 7 to 9. 
Identical fractions from a sucrose-D20 gradient analysis of NP-40 
treated unlabeled EIAV were pooled, and the proteins in the pool were 
TCA precipitated and subsequently analyzed on SDS-PAGE. The results 
of SDS-PAGE analysis of proteins contained in the subparticle and 
those solubilized by the detergent are presented in Figure III-lIB.
Figure III-l1: RNP preparation and analysis. (A) Sucrose-D20
3gradient analysis of RNP prepared from [ H]-leucine EIAV.
(B) SDS-PAGE analysis of RNP fractions and soluble fractions 
obtained from unlabeled EIAV and stained with coomassie blue. 




The ribonucleoprotein subparticle contains all of the virion pll, some 
of the EIAV ppl5, p26 and a few high molecular weight components (p30, 
p61 and p70), while the solubilized proteins consist of gp90, gp45, 
p26, ppl5 and p9, but no pll.
The total absence of pll in the detergent solubilized portion and 
its presence in subparticle fractions indicated it to be the major 
component of the ribonucleoprotein complex. Some amount of ppl5 and 
p26, observed in the ribonucleoprotein fractions, may reflect their 
specific association with RNA or pll or may result from incomplete 
dissociation by the detergent. The fact that pll is a basic protein 
favors the idea that it is associated with negatively charged RNA 
genome. The ppl5 is a phosphoprotein and, as in other retroviruses 
(Sen and Todaro, 1977), may have a specific affinity for RNA.
However, most of the ppl5 and p26 are solubilized by the detergent, 
and hence their predominant location cannot be in the 
ribonucleoprotein. Thus, the results obtained here are similar to 
those observed with ribonucleoprotein particles isolated from avian 
(Bolognesi, 1974; Davis and Rueckert, 1972) and murine (Bolognesi, 
1974) oncornaviruses, in which the basic internal protein is tightly 
bound to the viral RNA genome.
The presence of several high molecular components (MW = 30,000 to 
70,000) which purified with the RNP, but were absent from the 
detergent-solubilized portion, suggests their exclusive location in 
the RNP and may indicate a role as components of the virion reverse 
transcriptase or as uncleaved polyprotein precursors of the internal 
proteins (Montelaro and Bolognesi, 1978). These minor proteins were
3detected previously in [ H]-leucine EIAV preparations (Figure III-1A, 
Table III-l), but their significance was not known.
3. Inner Coat
In avian and murine oncornaviruses, the virion phosphoprotein is 
believed to comprise the inner coat structure underneath the lipid 
envelope (Montelaro and Bolognesi, 1980). In EIAV, a small amount of 
ppl5 always elutes with the lectin binding fractions when glycosylated 
and non-glycosylated proteins are separated on lectin affinity column 
(see below), although ppl5 is not glycosylated. This may reflect its 
affinity for envelope components such as gp45 and may also suggest its 
location just underneath the envelope in the inner coat. However, 
this does not exclude its location elsewhere in the virion.
4. Model of EIAV
  \
From these localization studies, a model of EIAV can be proposed 
as shown in Figure 111-12. Knob and spike structures of the virion 
are believed to be made of two glycoproteins, gp90 and gp45, which are 
known to be present on the outside of the lipid envelope. Like avian 
gp35 and murine pl5E, the poorly glycosylated hydrophobic protein, 
gp45, may be a transmembrane protein spanning the bilayer. Underneath 
the lipid bilayer is the inner coat, probably made of phosphoprotein, 
ppl5. The icosahedral core structure of the virion contains p26, the 
major virion structural protein, and perhaps also p9. Within the core 
shell is the helical viral RNA genome with pll and reverse 
transcriptase molecules closely associated to constitute the 
ribonucleoprotein complex.
Figure 111-12: A tentative model of EIAV proposed on the basis of
localization experiments. RT = reverse transciptase.
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Thus, the properties of constituent polypeptides and limited 
studies of the localization have permitted a tentative model of EIAV 
which is analogous to model of type-C retroviruses (Montelaro and 
Bolognesi, 1980).
IV. A SEARCH FOR ANTIGENIC VARIATION IN EIAV
EIAV Isolates
EIAV isolates were recovered from experimentally inoculated 
ponies in which the Wyoming (parental) strain of EIAV was serially 
passaged (Orrego et al., 1982). Sources of these isolates are 
demonstrated in Figure II-l showing isolate designation, inoculation/ 
replication path and the passage number. Second passage and third 
passage isolates (P2-1, P2-6 and P3-1, P3-3, respectively) were 
recovered from chronically 111 ponies demonstrating periodic episodes 
of disease. Daily rectal temperature plots of these ponies (Orrego,
1983) are shown in Figure 111-13, in which panel A represents 
temperature profile of a second passage pony. Two isolates, P2-1 and 
P2-6, used in this investigation, were recovered from plasma samples 
of this pony during the first and sixth fever episodes, respectively, 
as shown. Panel B contains a temperature plot of a third passage pony 
from which EIAV isolates P3-1 and P3-3 were recovered. The results of 
Orrego (1983) demonstrated that these isolates are distinct in 
neutralization assays, in agreement with the data of Kono et al.
(1971, 1973), and hence are good candidates for the study of antigenic 
variation. For the biochemical work presented here, viruses recovered 
from endpoint dilutions of plasma collected were propagated in fetal 
equine kidney cells and purified by standard procedures.
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Figure 111-13: Rectal temperature plots of (A) second passage and
(B) third passage ponies undergoing febrile episodes (Orrego,
1983). Viral inoculum and recovered virus isolates used in this 
investigation are shown.
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Comparison of EIAV Isolates
Antigenic variation can be studied by analyses of the component 
proteins by SDS-PAGE (Kew et al., 1981; Nottay et al., 1981) and by 
peptide mapping procedures (Scott et al., 1979; Kew et al., 1980).
Both of these techniques are used here to compare the major antigens 
of EIAV isolates.
(a) Analysis by SDS-PAGE
The polypeptide composition of the six virus strains was 
initially compared by SDS-PAGE analysis. The data presented in Figure 
111-14 demonstrates no major differences among the polypeptides found 
in parental and other EIAV isolates; the apparent molecular weights 
and relative stoichiometry of the major virion proteins p26, ppl5, pll 
and p9 are indistinguishable. Because of the complex protein profile 
in the region of the gel containing gp90 and gp45, it was difficult to 
compare these components from SDS-PAGE of whole virus preparations. 
Thus, the virion glycoproteins and nonglycosylated proteins were 
separated on Sepharose bound Lens culinaris (lentil) lectin. As 
reported in detail previously (Montelaro et al., 1983), the affinity 
chromatography fractionation of EIAV accomplishes the efficient 
separation of nonglycosylated and glycosylated virion components. 
Glycosylated virion components (binding fractions) of EIAV isolates 
along with that of parental strain are analyzed by SDS-PAGE (Figure 
111-15). The glycoprotein fractions contain the virion gp90 and gp45, 
a few other nonviral glycoproteins, and a small amount of EIAV ppl5.
In contrast, the nonbinding fraction contains essentially all of the 
virion p26, ppl5, pll and p9 components and a number of other minor 
virion associated proteins (data not shown).
Figure 111-14: SDS-PAGE analysis of proteins of EIAV isolates stained
with cooraassie blue. Parental EIAV is included for comparison.
# ppl5
Figure 111-15: SDS-PAGE analysis of glycoprotein pools of EIAV
isolates, stained with coomassie blue. Parental EIAV 
glycoprotein pool is included for comparison.
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The following observation can be made from the results shown in Figure 
111-15: i) Variable amounts of glycoproteins are recovered from
different isolates, starting with approximately the same amounts of 
viral proteins (about 2 mg in each case). This may reflect differing 
solubility of viral glycoproteins present in these viruses, ii) The 
respective glycoproteins, especially gp90, demonstrated different 
migration rates and differences in band width, suggesting structural 
alterations, iii) The gp45 band, in most cases, is very faint, 
migrating as a doublet (see parental EIAV) in 7.5% acrylamide gels.
The generally low recovery of gp45 may be due to its low affinity for 
lectins and its hydrophobic, insoluble nature.
Analysis by Two-Dimensional Peptide Mapping
Although the SDS-PAGE analysis of EIAV proteins indicated some 
structural variation in glycoproteins, a more definitive and 
informative approach is necessary to detect structural alterations 
related to antigenic variation in EIAV. From the SDS-PAGE analysis of 
whole virions (Figure III-I4) and their respective glycoprotein pools 
(Figure 111-15), protein bands corresponding to gp90, gp45 and p26 
were excised from all the EIAV isolates, radioiodinated and digested 
with trypsin in situ, and the resultant radioactive tryptic peptides 
analyzed by two dimensional mapping procedures, according to the 
methods of Elder et al. (1977a). In some cases, EIAV ppl5 and p9 were 
also mapped by the above procedure. The comparative analysis carried 
out here (Figure 111-16, 111-17, and 111-19) represent a pairwise 
study of the virus isolates involving a virus isolate and the 
preceding virus strain from which it originated, and these pairs are 
identified by arrows in the figures.
97
Analyses of gp90
Comparative peptide maps of the gp90 components of EIAV isolates 
are presented in Figure 111-16 in which the parental EIAV gp90 map is 
also included for reference. Examination of the gp90 peptide maps 
reveals that PI-1 gp90 is very similar to parental gp90. Prominent 
peptides migrate at the same position on two-dimensional maps with 
only a few differences. Two peptides are deleted (open circles) and 
two are labeled very poorly (broken circles) when Pl-1 gp90 map is 
compared to Parental EIAV gp90 map. Differences between the maps also 
include 2 peptides which are new to Pl-1.
The gp90 molecule showed many differences when Pl-1 was 
inoculated in a second passage pony to generate P2-1. These include 6 
new peptides not seen previously (Pl-1 gp90 map), two deletions and 
two sites where peptides seem to have rearranged (compare P2-1 map to 
Pl-1 map).
The replication of P2-1 in the second passage pony produce the 
P2-6 isolate. The P2-6 gp90 map showed deletion of two peptides and 
only one new peptide, when compared to the P2-1 gp90 map.
The P3-1 gp90 was different from the P2-1 gp90 molecule as seen 
from their peptide maps where P3-1 gp90 showed four deletions, one 
poorly labeled peptide and one area of peptide rearrangement. The 
P3-1 gp90 map had a high background, and as a result certain areas 
indicated with a question mark could not be compared. In contrast, 
the P3-3 gp90 gave a clean map demonstrating 3 new peptides, one 
deletion and one very poorly labelled peptide relative to its 
predecessor P3-1. A clean gp90 map from P3-3 is perhaps a reflection
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Figure 11-16: Comparative two-dimensional peptide map analysis of
125I-labeled gp90 digests of EIAV isolates. Parental EIAV gp90 
map is included as a reference. (O) missing peptides, (CO 
peptides with, decreased labeling, (►) new peptides and (-*) 
rearranged peptides. E = electrophoresis, C = chromatography.
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of the fact that the gp90 molecule from this isolate gave a 
comparatively tight band on SDS-PAGE, showing less heterogeneity.
From the results shown here it seems there are alterations in 
glycoprotein structure associated with EIAV antigenic variation. 
Moreover, there appears to be more alterations in the gp90 molecule 
when virus was adapted to another animal than when allowed to 
replicate in a single animal.
Analyses of gp45
Comparative peptide maps of the gp45 components of the EIAV 
isolates are presented in Figure 111-17.
When the Pl-1 gp45 is compared to parental EIAV gp45, one new 
peptide is evident while another one is labeled very poorly. There is 
also one area of peptide rearrangement. However, the Pl-1 gp45 map 
had a high background in some areas, and, consequently comparisons 
cannot be termed definitive. Relative to Pl-1, the P2-1 gp45 gave a 
peptide distribution showing two new peptides, one probable deletion 
and one area of peptide rearrangement. Here also there was one 
questionable area due to high background. In going from P2-1 to P2-6, 
the gp45 gave a map with one peptide showing altered mobility and one 
probable deletion. Compared to P2-6, the P3-1 gp45 showed two 
additional peptides, one deletion and two peptides which labeled 
poorly, in addition to two areas of some altered distribution as 
marked. In contrast P3-3 gave a map showing only 3 additions compared 
to the P3-1 gp45 map; all other peptides were identical.
It was noted that the recovery of gp45 from the virus isolates 
was very poor and this may have contributed to the high backgrounds of 
certain two-dimensional maps, making reliable comparisons difficult.
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Figure 111-17: Comparative two-dimensional peptide map analysis of
125I-labeled gp45 tryptic digests of EIAV isolates. Parental 
EIAV gp45 map is included as a reference. (O) missing peptides, 
(O) peptides with decreased labeling, (►) new peptides and (-») 
rearranged peptides. E = electrophoresis, C = chromatography.
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In any case, alterations appear to occur among the gp45 molecules from 
various virus strains and this variation may be important with regards 
to antigenic variations in EIAV.
Glycopeptides
The results presented above demonstrate that EIAV glycoproteins
change during virus replication in an animal but give no information
whether the changes involve glycosylated or nonglycosylated regions of
the polypeptide. For this purpose, it is important to know which of
the peptides in the gp90 map are glycosylated and which are
125nonglycosylated. Thus, an I-labeled tryptic digest of the P2-6 
gp90 was separated into glycosylated and nonglycosylated pools by 
affinity chromatography on lentil lectin as described (Montelaro et 
al., 1982), and the binding and nonbinding peptide pools were analyzed 
by two dimensional peptide mapping procedures. The nonglycosylated 
peptides produce a map (Figure III-18A) representing a partial gp90 
map (compare Figure 111-16, P2-6 map). However, when the glycosylated 
peptides are analyzed by the same procedure, it was found that the 
radioiodinated peptides of gp90 were resolved only poorly during 
electrophoresis, and failed completely to chromatograph in the second 
dimension (Figure III-18B). This observation was confirmed by peptide
3analysis of a digest of purified [ H]-glucosamine labeled gp90 (Parekh 
et al., 1980) (Figure III-18C). This poor resolution precluded any 
comparison of glycopeptides by this mapping procedures. It also 
indicated that the differences observed in the maps of radioiodinated 
gp90 probably do not involve glycosylated peptides. Thus, further 
structural alterations may be detectable upon analysis of
A B C
Figure 111-18: Two-dimensional peptide analysis of gp90 digest.
125(A) I-labeled lectin nonbinding (nonglycosylated) peptides. 
125(B) I-labeled lectin binding (glycosylated) peptides.
3(C) [ H]-glucosamine labeled gp90 digest.
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glycopeptides by gel filtration chromatography and/or HPLC techniques 
(Hunt et al., 1981).
Analyses of Internal Antigens
The major internal protein, p26, recovered from SDS-PAGE analysis
of these virus isolates was mapped and the results are shown in Figure
111-19. Parental EIAV p26 and Pl-1 p26 gave identical maps; no
125detectable changes in the tryosine containing I-labeled peptides 
are evident. When the Pl-1 p26 map is compared to P2-1 p26, all of 
the major peptides are found to be identical, except one in P2-1 which 
was not apparent in the Pl-1 p26 map. When p26 molecules from the 
P2-1 and P2-6 are compared, they gave very reproducible maps 
demonstrating no changes in this molecule during replication in the 
pony. However, comparison of p26 from P2-1 and P3-1 did indicate some 
changes in the molecule. Thus this major internal protein seems to 
have undergone structural alteration when the virus was transferred 
from one animal to another. In contrast, P3-3 produced a p26 map 
identical to the P3-1 p26, suggesting that this molecule is conserved 
while the virus is replicated in a single animal.
In addition to p26, P2-1 p9 was mapped by identical procedures 
and found to have peptide maps identical to the analogous parental 
antigen (Figure 111-21). Also, P2-1 ppl5, P3-1 ppl5 and P3-3 ppl5 
were mapped to see if the observed alteration in p26 extended to other 
internal antigens. This molecule from all three isolates gave maps 
identical to parental ppl5 (Figure 111-20). These results indicate 
that ppl5 and perhaps p9 do not change during backpassaging of the 
virus or replication in a single pony.
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Figure 111-19: Comparative two-dimensional peptide analysis of
125I-labeled p26 tryptic digests of EIAV isolates. Parental EIAV 
p26 map is included as a reference. (►) new peptides and 
(-*) rearranged peptides. E = electrophoresis, C = 
chromatography.
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Figure 111-20: Comparative two-dimensional peptide analysis of
125I-labeled ppl5 tryptic digests of some EIAV isolates. 
Parental EIAV ppl5 map is included as a reference.
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Parental EIAV
125Figure 111-21: Two-dimensional peptide analysis of I-labeled p9
trypitc digests of parental EIAV and P2-1.
CHAPTER IV
DISCUSSION
The experiments described in this investigation have enabled us 
to achieve the following goals.
a) Identification of the major and minor structural polypeptides of 
EIAV.
b) Characterization of the major polypeptides with respect to their 
secondary modifications (e.g. glycosylation, phosphorylation), 
isoelectric points, peptide analyses and a few other characteristic 
properties.
c) Assignment of the major polypeptides to specific locations in the 
intact virion and the proposal of a tentative model for EIAV.
d) An analysis of the molecular nature of antigenic variation in EIAV 
by peptide mapping of antigens of EIAV isolates recovered from febrile 
episodes in experimentally inoculated ponies.
Previous workers typically used only one method for EIAV 
polypeptide analysis and molecular weight estimation. In contrast, 
the complementary techniques of guanidine hydrochloride gel filtration 
and high resolution SDS-PAGE have been used in this investigation to 
resolve EIAV structural polypeptides. This was very useful since low 
molecular weight polypeptides, especially ppl5 and pll, resolved 
better on GHCl-GF than on SDS-PAGE. Also, the results obtained by 
these two techniques were used for molecular weight estimations and 
nomenclature as recommended by August et al. (1974). Our experiments 
demonstrated that EIAV grown in fetal equine kidney cells contains six
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major polypeptides and four minor components. The major polypeptides 
included 2 glycoproteins and four nonglycosylated polypeptides.
Cheevers et al. (1978) reported the presence of four 
glycoproteins gp77/79, gp64., gp40 and gplO, the first three of which 
were major structural components. In contrast, we demonstrate that 
EIAV contains only two glycoproteins, gp90 and gp45, which together 
represented less than 10% of the virion proteins. Ishizaki et al. 
(1978) concluded that EIAV contains two major glycoproteins,
3designated as gp80 and gp40, while the [ H]-glucosamine labeled peak 
obtained in the region of gplO was attributed to glycolipid.
It seems likely that the gp64 component reported by Cheevers et 
al. (1978) most probably represented glycoprotein from tissue culture 
system which copurifies with the virus. In our analysis, we found
3that partially purified [ H]-glucosamine labeled virus preparations 
contain a glycoprotein analogous to gp64 which is present in varying 
amounts, but absent after further purification of the virus by 
isopycnic centrifugation. Also analysis of supernatants from 
uninfected kidney cells demonstrated the presence of an analogous 
component. Thus, this glycoprotein was not considered to be an 
integral component of the purified EIAV.
Cheevers et al. (1978) and Ishizaki et al. (1978) also reported 
that EIAV contains two (p29 and pl3) and three (p25, pl4 and pll) 
major nonglycosylated polypeptides, respectively, as analyzed by 
SDS-PAGE. Examinations of the polypeptides of visna virus, a 
prototype lentivirus, similarly revealed two (Bruns and Frenzel,
1979) or three (Lin, 1977; Scott et al., 1979) major nonglycosylated 
proteins. Based on these observations it has been suggested that
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polypeptide composition may serve as a distinguishing feature between 
the lentivirus and oncornavirus subfamilies of the family Retrovividae 
(Matthews, 1979). However, we reported here that EIAV contains four 
major nonglycosylated proteins designated p26, ppl5, pll and p9.
These findings are in agreement with those of Charman et al. (1979), 
who resolved four structural components [p26, pl2, plO (acidic) and 
plO (basic)] by isoelectric focussing.
We further confirmed that our improved resolution of major 
nonglycosylated polypeptides is not the result of degradation or 
cleavage of one polypeptide into another, as limited proteolytic 
digestion with two different enzymes, chymotrypsin and J3. aureus V8 
protease, produced unique peptides from each of these polypeptides. 
Also exhaustive digestion of radioiodinated polypeptides with trypsin 
yielded peptides which displayed different two dimensional 
maps, characteristic of each polypeptide and demonstrating no 
relatedness. Thus p26, ppl5, pll and p9 are unique structural 
components of EIAV.
That these major structural proteins are coded by the virus and 
are not cellular or serum proteins incorporating into the virus 
structure was deduced by the following observations.
a) When infected cells are metabolically labeled with radioactive 
leucine, even for a short term, purified EIAV demonstrated the 
presence of gp90, gp45, gp26, ppl5, pll and p9.
b) The proportion of these polypeptides in purified virus preparation 
was constant, as determined by the amount of the radioisotope 
incorporated. A polypeptide fortuitously copurifying with virions 
will not always be in the same proportion.
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c) When EIAV was grown on different cell types, e.g. fetal equine 
kidney cells or equine dermal cells, purified virus always displayed 
identical major polypeptides.
d) Artifically or naturally infected horses suffering with chronic 
EIA developed antibody responses to all the major antigens described 
here. Hence these proteins can not be host cell derived, but must 
represent proteins coded by the viral genome.
Our results also conclusively demonstrate that EIAV, a putative 
lentivirus, contains polypeptide composition analogous to type-C 
viruses, like oncornaviruses, in spite of the lack of cross-reactivity 
between EIAV and any other known virus belonging to the Retroviridae 
(Charman et al., 1976; Dalton, et al., 1975; Stowring et al., 1979). 
Other members of the Retrovirus family with similar properties, but 
unique serological specificities, are bovine leukemia virus (BLV), 
Mason-Pfizer monkey virus (MPMV) and mouse mammary tumor virus (MMTV) 
(Charman et al., 1976). Although the above viruses are usually not 
considered C-type viruses on morphological grounds, it is known that 
avian oncornaviruses, which represent true C-type viruses, are also 
unrelated serologically and biochemically to mammalian oncornaviruses.
Cheevers et al. (1980) reported that only EIAV gp79 located is on 
the outside of the lipid envelope, while the other two reported 
glycoproteins, gp64 and gp40, are internal. Localization studies 
carried out in this investigation clearly demonstrated that both gp90 
and gp45 can be labeled by surface labeling procedures and are also 
susceptible to protease digestion in the intact virions, indicating 
that they are on the outside of the lipid envelope.
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Several reports have described a high degree of similarity 
between gp71 and a minor component gp45 in murine leukemia virus.
Elder et al. (1977a) reported that gp45 and gp71 generated identical 
tryptic peptides, and hence differ only by the lower carbohydrate 
content of gp45 (Marquadt et al., 1977). Other workers, however, have 
indicated that gp45 is derived from gp71 by proteolytic cleavage, 
probably at the carboxyl end (Henderson et al., 1978). Our results 
with EIAV gp90 and gp45 showed that these glycoproteins gave very 
different tryptic peptide maps and, thus, are not related to each 
other by common amino acid sequences. This was in contrast to 
Cheevers et al. (1980) who concluded that EIAV glycoproteins (gp79, 
gp64 and gp40 as reported) are related. However, these investigators 
made no attempts to purify EIAV glycoproteins before they were mapped. 
Considering the low amounts of these proteins present in the virion, 
and comigrating proteins on SDS-PAGE (Montelaro et al., 1983), 
complete purification Is essential. In the case of avian viruses, 
Mosser et al. (1977) demonstrated by peptide mapping analysis that 
gp35 is not a cleavage product of gp85. In this respect EIAV 
resembles avian type-C viruses.
An interesting observation from our studies was that EIAV gp45 
separated into two bands in SDS-PAGE, but that the two bands of gp45 
gave identical maps on peptide analysis. Qualitative/quantitative 
differences in the glycosylation of the same polypeptide may result in 
a doublet. In MMTV, a type-B retrovirus, gp36 often migrates as a 
doublet in SDS-PAGE, which when subjected to tryptic peptide analysis 
gave identical maps (Dickson et al., 1976). It was later shown that
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resolvable species of gp36 differed in their carbohydrate content 
(Yagi et al., 1978).
Compared to EIAV gp90 and gp45, analogous surface components in 
avian type-C viruses are gp85 and gp35 while in murine viruses they 
are gp71 and pl5E/pl2E. Both avian gp35 and murine pl5E molecules are 
hydrophobic like EIAV gp45 and require detergents to keep them in 
solution. Thus, hydrophobic gp45 may span the lipid bilayer, while 
the heavily glycosylated gp90 may be more exposed to the outside. 
However, unlike avian viruses where greater than 90% of gp85 and gp35 
are disulfide linked into a viral glycoprotein complex (Leamnson and 
Halpern, 1976; Montelaro, et al., 1978), EIAV glycoproteins are not 
disulfide linked. In Murine virus FLV, only a small fraction of gp71 
molecules is disulfide linked to pl5E in a complex (Montelaro et al., 
1978).
Several workers have reported the major group specific antigen of 
EIAV as a polypeptide with a molecular weight of 25,000 - 29,000 
daltons (Barta and Issel, 1978; Cheevers et al., 1978; Ishizaki et 
al., 1978). Here it has been termed as p26. EIAV p26 appears to be 
the major internal component analogous to avian virus p27 and murine 
virus p30 (Table IV-1), partially constituting the icosahedral core 
shell that lies beneath the lipid envelope and surrounds the RNP.
EIAV p26 displayed a pi of 6.2 upon isoelectric focussing. Analagous 
p30 of various mammalian type-C viruses displayed pi values ranging 
from 6.2 to 8.0 (Stephenson et al., 1977).
Murine and avian retroviruses contain basic polypeptides plO and 
pl2, respectively, which are believed to be associated with genomic 
RNA in a ribonucleoprotein (RHP) complex. Our results demonstrated
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Table IV-1: Analogous polypeptides of EIAV, murine type-C (FLV) and






gp90 8P71 gp85 ") Envelope
gp45 pl5E/pl2E gp35 J
p26 p30 p27 Core shell
PP15 PP12 PP19 Inner coat
pll plO pl2 RNP complex
p9 pl5 pl5 Core associated
* Montelaro and Bolognesi (1980).
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the presence of such a basic polypeptide, pll, in EIAV as part of its 
RNP complex. Davis and Rueckert (1972) presented evidence that the 
fast sedimenting component isolated from NP-40 treated Rous sarcoma 
virus (RSV) is RNP. This particle contained the viral 60S to 70S RNA 
and some 4S RNA (host tRNAs) in a complex with a few viral 
polypeptides. Several electron microscopy studies of RNA tumor virus 
structure have presented evidence that the RNP is a coiled filament 
(Bonar et al., 1964; de-The' and O'Connor, 1966; Lacour et al., 1970; 
Nowinski et al., 1970). Sarkar et al. (1971) and Bolognesi et al. 
(1978) proposed a general model for RNA tumor virus ultrastructure in 
which the filamentous RNP is packaged within the virus core in a 
helical configuration. The basic nature of EIAV pll and its location 
in RNP suggest that the polypeptide may function in packaging of the 
genomic RNA or may affect the expression of the genome during 
infection.
Long et al. (1980) reported the presence of a basic polypeptide 
in EIAV that binds to single-stranded calf thymus DNA and apparently 
is analogous to pll reported here. However, that was the smallest 
EIAV polypeptide they resolved on SDS-PAGE, whereas our results 
indicated that it is the second smallest polypeptide of EIAV. As 
before, p9 was not resolved by these workers. This polypeptide, in 
contrast, is acidic and is not a component of the RNP.
The RNP substructure isolated from EIAV contained a few other 
polypeptides in addition to pll (Figure III-12B). However, only some 
of these polypeptides were enriched in RNP compared to whole virus 
preparation, such as p30, p61 and p70. These proteins, like pll, were 
completely absent in the solubilized protein portion which contained
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all of virion gp90, gp45 and most of the p26, ppl5 and p9. Other 
polypeptides in the RNP may represent genome associated reverse 
transcriptase (Montelaro and Bolognesi, 1980) and/or uncleaved 
polyprotein precursors. Reverse transcriptase of retroviruses is 
present in about 20-70 copies per virion (Krakower et al., 1977; Panet 
et al., 1975). Two polypeptides contained in RNP, p61 and p70, are 
present in about 60-70 copies each per virion (Table III-l). These 
suggest that either one or both may represent EIAV reverse 
transcriptase. A 70,000 daltons polypeptide has been identified from 
EIAV to contain reverse transcriptase activity (Archer et al., 1977; 
Charman et al., 1976; Cheevers et al., 1978).
Based on the evidence of phosphorylation (Montelaro et al.,
1982), EIAV ppl5 may be the analog of avian ppl9 and murine ppl2 
(Table IV-1). Murine ppl2 was shown to be present in several 
different but specific phosphorylated states (Hayman et al., 1977; Pal 
et al., 1975). EIAV ppl5 displayed a heterogeneous but reproducible 
pattern on isoelectric focussing gels which may correlate with the 
degrees of phosphorylation of the molecule.
Avian ppl9 and murine ppl2 are believed to comprise the inner 
coat in the respective viruses (Bolognesi et al., 1978). EIAV ppl5 
may also constitute the analogous inner coat structure. Our results 
indicated that some amount of ppl5 always eluted in the binding 
fractions along with viral glycoproteins when detergent disrupted EIAV 
was analyzed on lectin affinity chromatography, suggesting some 
affinity to glycoprotein(s). This affinity may reflect its location 
close to glycoproteins underneath the lipid bilayer. Lactoperoxidase 
catalyzed surface radioiodination of the intact virus resulted in
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major labeling of glycoproteins and minor incorporation into ppl5 
(Figure 111-10). Thus ppl5, to a small extent, is accessible to 
this surface labeling technique. All of these results collectively 
support the idea that ppl5 forms the inner coat structure.
At least a few molecules of retrovirus phosphoprotein are 
believed to be associated with RNA genome by highly specific 
interactions (Sen and Todaro, 1977; Pal and Roy-Burman, 1975). The 
presence of a small amount of ppl5 in the RNP of EIAV indicates that 
it may be a possible RNP component. But it may also bind RNA as a 
result of the detergent disruption.
EIAV p9 was found to be an acidic polypeptide with pi of 5.0.
The analogous polypeptide in avian and murine viruses is the remaining 
gag gene coded internal protein, pl5 in both cases. Murine pl5 is 
hydrophobic and has a pi of 7.5, and the avian pl5 is a protease with 
pi of 6.6. The exact location of EIAV p9 is not determined, but 
tentatively has been assigned to icosahedral core because of its 
absence both in RNP and on the outside of the lipid envelope.
Initial biochemical characterizations of EIAV polypeptides 
provided a foundation to study the process of antigenic variation in 
this retrovirus. Major attention was focussed on the surface 
glycoproteins gp90 and gp45 which are believed to be the main targets 
of the neutralizing antibodies, although certain nonglycosylated major 
internal polypeptides were also studied. Glycosylated proteins were 
separated from nonglycosylated components by lectin affinity 
chromatography as described (Montelaro et al., 1983). The lectin 
isolated from Lens culinaris, a common lentil, has a binding 
specificity for a-glucopyranosyl and a-mannopyranosyl residues.
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Binding of EIAV glycoproteins to this lectin was easily reversed by 
inclusion of a-methylglucoside in the elution buffer. Thus, lentil 
lectin effectively separated EIAV glycosylated and nonglycosylated 
polypeptides with recoveries of about 65%.
Similar protocols were followed for EIAV isolates recovered from 
infected ponies. Although more than 80 EIAV isolates were recovered 
from infected animals (Orrego, 1983), only five of these were 
selected, in addition to the parental EIAV strain, for a judicious 
comparative study of possible antigenic variations presented here. 
Selection of isolates was based primarily on two criteria.
1) Study of the proposed antigenic variation within an infected 
animal.
2) Study of the antigenic variation on subsequent passaging of the 
virus in different animals.
Orrego (1983) demonstrated that the isolates chosen here were 
serologically distinct in virus neutralization assays and consequently 
were good candidates for antigenic variation studies.
From the tryptic peptide maps of gp90, it was observed that there 
were a few reproducible changes detected during replication in an 
infected animal (Figure 111-16, see P2-1 and P2-6; P3-1 and P3-3). 
However, more variation was observed when the virus was transferred 
from one animal to another than during replication in a single animal 
(Figure 111-16, compare Pl-1 and P2-1; P2-1 and P3-1). It seems that 
this adaptation to physiological environment of a different animal 
results from more mutational events than that observed during 
sequential febrile episodes in the infected animal. Since all the 
isolates recovered from a single pony were not studied, it is not
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possible to suggest how many changes may actually result in the 
appearance of a new isolate, but these kinds of studies will indeed be 
helpful.
The results obtained upon analyses of EIAV gp45 (Figure 111-17) 
indicated that this molecule also undergoes structural alterations, 
thus contributing to antigenic variation. As in the case of gp90, 
more variation was observed in the gp45 molecule when the virus was 
transferred from one animal to another. However, some of the gp45 
maps (Pl-1, P2-1) had high background, thus hampering a definitive 
interpretation. The main reasons for this background problem are that 
only small amounts of gp45 could be recovered from EIAV isolates 
(Figure 111-15) and secondly, contaminating components from acrylamide 
incorporate label and contribute to the background (Elder et al., 
1977b).
Although the major internal proteins did not show alterations 
when the Wyoming strain of EIAV was adapted to animals, EIAV p26 
demonstrated some variation when the virus was further passaged from 
one animal to another (Figure 111-19). Thus, on second back 
passaging, p26 showed one new peptide (P2-1 map) that was absent in 
Pl-1. On third back passaging, more variations in p26 were observed 
(compare P3-1 to P2-1). However, alterations were limited to 
adaptation of the virus to another animal and were not seen when the 
virus was replicated in a single animal for a long period. No 
accompanying variation was observed in EIAV ppl5 and p9 which yielded 
reproducible peptide maps.
EIAV p26 is a major internal antigen of the virus and is not 
believed to be a target for neutralizing antibodies. Selection and
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amplification of EIAV variants may be under immunological pressure, 
but this should not account for alterations in p26 molecule. Thus, it 
would appear that random mutational events in the genome of EIAV led 
to these changes which also included selective alterations in the 
envelope proteins. The exact nature of the selective pressure exerted 
on viruses replicating in animals is poorly defined. It is very 
likely that factors other than host antibodies may also play a role 
(Palmenberg et al., 1979; Kew et al., 1981). In the case of 
poliovirus, changes in the virus polypeptides were not restricted to 
the structural proteins, but were also observed in the non-capsid 
proteins functioning only intracellularly (Kew et al., 1981).
Retroviruses can evolve in response to altered selection 
pressure. This was confirmed from the observation that when cloned 
ASV was repeatedly passaged in cultures of chicken cells, 
oligonucleotide maps of the genomes of the virus preparations 
recovered were found to be altered (Coffin et al., 1980), although the 
altered region of the genome was not determined. However, all avian 
viral proteins exhibit some degree of polymorphism. Variations are 
often detected when genomes or analogous gene products of different 
strains of virus are examined by techniques such as oligonucleotide 
mapping, peptide mapping, radioimmunoassay and SDS-PAGE (Bhown et al., 
1980; Shaikh et al., 1978, 1979). In the case of MMTV, a B-type 
retrovirus, gp52 and p27 from different strains have been shown to 
possess structural differences. It is possible that different strains 
of a virus are generated by accumulation of alterations in the genome. 
Recombination with endogenous genomes can also play a role in the 
generation of polymorphic forms.
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There are no reports indicating that EIAV undergoes antigenic 
variation when grown in tissue culture. Also, we have found no 
evidence that in tissue culture EIAV polypeptides are altered by 
repeated passage. The tryptic peptide maps of the major antigens of 
EIAV have been found to be completely reproducible in different 
preparations of the virus grown in tissue culture and remained 
unaltered on repeated subpassaging.
With regards to antigenic variation in EIAV, it was realized that 
the changes in peptide maps of EIAV antigens detected here are 
not necessarily comprehensive, since the procedure detected only 
tyrosine containing peptides. Variations in the regions of 
polypeptide lacking tyrosine may go undetected. Also, the results 
indicated that the resolved peptides are, most probably, not 
glycosylated (Figure 111-18). Thus, it is very likely that there may 
be additional differences, especially in the glycosylated region of 
the polypeptides. The use of different enzymes for generation of 
peptides, glycoprotein labeling with radioactive sugars and the use of 
HPLC for peptide analysis should provide additional information 
relative to the biochemical nature of the antigenic variation detected 
in these studies.
While the analyses of EIAV polypeptides for the study of 
antigenic variation promises to be informative, these results need to 
be correlated at the level of viral genome. Thus, oligonucleotide 
mapping of the RNAs from different EIAV isolates can determine the 
changes in the viral genome and thus, explain the basis of antigenic 
variation.
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Antigenic variation has not been reported in oncornaviruses, at 
least during replication in a single animal, although genetic changes 
do occur through recombination at a very high frequency resulting from 
a mixed infection (Coffin, 1980). Also the existence of different 
strains of viruses and occurrence of various strains in practically 
all organisms suggest that antigenic variation may be a normal process 
of evolution. The difference may be in the rate at which the 
antigenic variation occurs for a particular life form. In an animal, 
the obvious selection pressure is immunological, but there may be 
other less obvious ones. In nature there may be different constraints 
which exert varying degrees of pressure on different life forms to 
evolve. Antigenic variation, in a sense, seems one facet of the 
natural process of evolution.
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APPENDIX 1
AGID
•LIST OF ABBREVIATIONS 
Agar gel immunodiffusion
ASV Avian sarcoma virus
BSA Bovine serum albumin
DNP-ala 2,4-dinitrophenyl alanine
DPCC-trypsin Diphenyl carbamyl chloride treated trypsin
DOC 7-deoxycholate
EDTA Ethylene dinitrilo tetraacetic acid
EIA Equine infections anemia
EIAV Equine infections anemia virus
FLV Friend murine leukemia virus
GHC1-GF Guanidine hydrochloride gel filtration
HA Hemagglut inin
Idu Iododeoxyuridine
MMTV Mouse mammary tumor virus




RSV Rous sarcoma virus
SDS-PAGE Sodium dodeyl sulfate-polyacrylamide gel electrophoresis
TCA Trichloroacetic acid
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